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Summary 
Cells in a multicellular organism need to monitor their environment for 
nutritional cues, growth and stress signals in order to adapt their metabolism 
and growth to the changing conditions. The Target of Rapamycin (TOR) 
signaling pathway is an evolutionary conserved cellular protein network that 
controls responses to these signals. TOR signaling is a major research topic 
because of its role in several prevalent human disorders, including cancer and 
diabetes, but our understanding of TOR pathway is still far from complete. 
This work is aimed at improving our understanding of TOR signaling in two 
ways: by developing new research tools to dissect the dynamics of TOR 
signaling in cells and by characterizing the function of a novel component in 
the TOR pathway. 
The first chapter presents the project to develop a probe, based on the 
Fluorescence Resonance Energy Transfer (FRET) method, for measuring 
TOR activity in cell culture. I used several approaches to design a FRET 
probe, based on a substrate of TOR kinase called 4EBP1. These probes did 
not prove to be useful because fusions to fluorophore domains abolished 
biological regulation of 4EBP1. An alternative strategy whereby a small tag 
was introduced into 4EBP1 and then used for in vivo labeling, could solve this 
problem. Unfortunately, when this probe was expressed in the cells, its 
interaction with a corresponding partner did not produce a reliable FRET 
signal, as determined by three different methods. Nevertheless, the obtained 
results can be used as a basis for future attempts to develop probes for TOR 
kinase. 
The second chapter describes the genetic analysis of the MAP4K3 function in 
Drosophila. MAP4K3 is a new component of the TOR pathway proposed to 
mediate nutrient sensing by TOR. I identified a strong hypomorphic MAP4K3 
mutant and investigated the phenotypes caused by absence of this protein. 
MAP4K3 mutant flies were viable but weak. Mutant animals demonstrated 
delayed growth, reduced cell and organ size. Furthermore, they were lean, 
displaying reduced fat, which could be rescued by genetically increasing TOR 
activity. This suggests that the observed metabolic defect is due to low TOR 
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activity. The mechanism of MAP4K3 action may involve the MAP kinase 
pathway and/or modifying activity of Rag GTPases, which can interact with 
MAP4K3 in cell culture. These results establish MAP4K3 as a regulator of 
metabolism and growth and open up new possibilities for manipulating TOR 
signaling. 
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Zusammenfassung 
Die Zellen eines vielzelligen Organismus müssen ihre Umbegung auf 
Nahrungs-, Wachstums- und Stresssignale überwachen, um ihren 
Stoffwechsel und ihr Wachstum den sich wandelnden Bedingungen 
anzupassen. Der Rapamycin (TOR) Signalweg stellt ein evolutionär 
konserviertes zelluläres Proteinnetzwerk dar, welches die spezifischen 
Reaktionen der Zelle auf obige Reize kontrolliert. Die Signalübertragung 
durch TOR ist wegen seiner Rolle in mehreren weit verbreiteten menschlichen 
Krankheiten, darunter Krebs und Diabetis, ein wichtiges Forschungsgebiet, 
aber unser Verständnis des TOR Signalweges ist immer noch lückenhaft. In 
der vorliegenden Arbeit werden zwei Ansätze verfolgt, um unser Verständnis 
des TOR Signalweges zu erweitern: die Entwicklung neuer Werkzeuge zur 
Untersuchung des dynamischen Verhaltens des TOR Signalweges in Zellen 
und die funktionelle Charakterisierung einer neuen Komponente des TOR 
Signalweges.  
Das erste Kapitel stellt ein Projekt vor, im Rahmen dessen eine neue Sonde 
entwickelt wurde, die auf dem Prinzip des Flourescence Resonance Energy 
Transfer (FRET) beruht und mit deren Hilfe die TOR Aktivität von Zellen in 
Kultur gemessen werden sollte. Ich habe mehrere unterschiedliche Versuche 
unternommen, die Sonde auf dem TOR Kinase Substrat 4EBP1 basierend zu 
entwickeln. Diese Sonden konnten jedoch nicht für die Messungen verwendet 
werden, da die Fluorophordomäne die biologische Regulation  des 4EBP1 
beeinträchtigte. Durch eine andere Strategie, bei der ein kleinerer Affinitäts 
“tag“ in 4EBP1 eingeführt und für die in vivo Markierung verwendet wurde, 
konnte dieses Problem jedoch behoben werden. Leider zeigte diese FRET-
Sonde, wenn sie in Zellen exprimiert wurde, aber das Problem, bei Interaktion 
mit ihrem entsprechenden Bindungspartner kein zuverlässiges FRET Signal 
zu liefern, was durch drei unterschiedliche Methoden nachgewiesen wurde. 
Die gewonnenen Ergebnisse können jedoch als Ausgangspunkt für zukünftige 
Versuche genutzt werden, Sonden für die TOR Kinase zu entwickeln. 
Das zweite Kapitel beschreibt die genetische Untersuchung der Funktion von 
MAP4K3 in Drosophila. MAP4K3 ist eine neue Komponente des TOR 
Signalweges, der die Funktion zugeschrieben wird, das Aufspüren von 
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Nährstoffen durch TOR zu vermitteln. Ich habe eine starke hypomorphe 
Mutation in MAP4K3 identifiziert und den Phänotyp untersucht, den das 
Fehlen dieses Proteins verursacht. Fliegen mit der MAP4K3 Mutation waren 
lebensfähig, aber schwach. Sie wiesen ein verzögertes Wachstum und eine 
geringere Zell- nud Organgröße auf. Weiterhin waren sie übermäßig dünn und 
besaßen einen verminderten Körperfettanteil, was durch genetische 
Erhöhung der TOR Aktivität aufgehoben werden konnte. Dies legt nahe, dass 
der beobachtete Stoffwechseldefekt auf zu geringer TOR Aktivität beruht. Es 
ist möglich, dass für den Wirkmechanismus von MAP4K3 der MAP Kinase 
Signalweg eine Rolle spielt oder die Modulierung der Aktivität von Rag 
GTPasen, welche mit MAP4K3 in Zellkultur interagieren können. Die 
vorliegenden Ergebnisse etablieren MAP4K3 als einen Stoffwechsel- und 
Wachstumsregulator und eröffnen neue Möglichkeiten, den TOR  Signalweg 
zu manipulieren. 
 9 
1. Introduction 
1.1. Overview 
 
All cells must constantly assess their environment for various cues, such as 
availability of nutrients for growth or signs of stress that may interfere with 
normal growth. Successful evaluation of environmental conditions is crucial 
for taking appropriate decisions that may determine whether the cell lives or 
dies. Therefore, cells have evolved complex and robust mechanisms that 
enable them to detect, process and respond to environmental cues. Such 
mechanisms are implemented by networks of interacting proteins that 
transduce signals activating or repressing the necessary processes in the cell. 
Many of these signaling cascades often use phosphorylation – the transfer of 
a phosphate group, as means to propagate a signal. Kinases, the enzymes 
mediating phosphate transfer, are central players of these signaling pathways 
and understanding of the function and regulation of kinases is a primary goal 
of cell and molecular biology. 
This thesis deals with Target Of Rapamycin (TOR) kinase signaling, a 
pathway that has emerged as a critical node integrating many extracellular 
and intracellular cues to regulate growth and metabolism. After a general 
introduction to TOR signaling in and its functions, I will describe the two 
projects that constitute this thesis. The first project deals with developing a 
TOR kinase in vivo probe based on fluorescent visualization of biochemistry in 
live cells. The second project takes a genetic approach to assess the function 
of a new gene responsible for mediating nutrient sensing by TOR in 
Drosophola melanogaster. 
 
1.2.  TOR signaling – integration of external signals to 
coordinate metabolism and growth 
 
TOR is an evolutionary conserved Ser/Thr kinase first identified in yeast as a 
target of the immunosuppressant drug Rapamycin (Heitman et al., 1991). 
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Rapamycin is produced by Streptomyces hygroscopicus, a bacterium found in 
soil of the Easter Island (in local language - Rapa Nui), from which the name 
Rapamycin arises. Every eukaryotic genome so far examined (including 
yeasts, algae, slime mold, plants, worms, flies and mammals) has contained a 
TOR gene. Saccharomyces cerevisiae have two TOR genes, while mammals 
possess a single gene producing a protein called mammalian Target of 
Rapamycin - mTOR (Wullschleger et al., 2006).  
Since its discovery in the early 90’s, TOR has been implicated in a long list of 
fundamental cellular processes and attracts ever increasing scientific 
attention. The literature is extensive; the number of publications in PubMed 
having the keyword “TOR” is approaching 8000, with new articles published 
every week. TOR kinase integrates cues from both outside and inside the cell, 
including hormones, availability of nutrients, energy status, and hypoxia. TOR 
kinase regulates a wide variety of processes including growth and 
proliferation, translation and ribosome biogenesis, metabolism and autophagy 
(Sarbassov et al., 2005). Naturally, I will focus my attention on the processes 
regulated by TOR that are relevant to my work. 
One of the reasons TOR has become such a hot topic of research is its 
important role in development and disease. TOR is essential for organismal 
development, and its deficiency and in C.elegans and D.melanogaster leads 
to developmental arrest (Long et al., 2002; Oldham et al., 2000; Zhang et al., 
2000). Knockout of mTOR in mice results in embryonic lethality (Gangloff et 
al., 2004). Phenotypes of TOR mutant animals resemble phenotypes of amino 
acid starvation, highlighting its role in nutrient sensing.  
Dysregulation of the mTOR signaling pathway has been connected to a 
number of diseases, most prominently cancer and metabolic diseases. Many 
upstream regulators of TOR as well as downstream effectors are causally 
involved in cancer and the TOR pathway is considered an important target in 
cancer therapy (Bjornsti and Houghton, 2004a, b; Sabatini, 2006). Being 
regulated by insulin and feeding back to insulin signaling, mTOR is also an 
important player in metabolic disorders such as diabetes and obesity 
(Manning, 2004). 
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1.3. Upstream regulators of TOR signaling 
 
TOR functions as a multiprotein complex, where members of the complex 
define its identity and function. Two distinct complexes have been described. 
TOR complex 1 (TORC1) is a rapamycin-sensitive one that in mammals 
contains, in addition to mTOR kinase, raptor and mLST8 proteins and 
regulates ribosomal biogenesis, protein synthesis and growth. TOR complex 2 
(TORC2) is insensitive to rapamycin, contains rictor, mLST8 but not raptor 
and it is thought to regulate the actin cytoskeleton (Bhaskar and Hay, 2007). I 
will not further consider TORC2 as it is not directly connected to my work. 
Therefore, I will use the terms TOR and TORC1 interchangeably throughout 
this thesis. 
 
Insulin/growth factors regulation of TOR 
A simplified model of mammalian TOR signaling is presented in Figure 1. 
Molecular mechanisms of TOR regulation have been elucidated to a different 
extent for various upstream regulators. Insulin/IGF (Insulin-like Growth Factor) 
pathway is connected to TOR signaling, which is considered to have evolved 
later in multicellular organisms on top of the more ancient nutrient regulation 
of TOR. Cells must coordinate their actions with other cells within a tissue or 
an organ to allow coordinated behavior during development and growth. In 
animals, this is accomplished in part via insulin. Insulin and related hormones 
(e.g. IGF) are systemic hormonal signals that bind to the receptors on the cell 
surface and initiate a signaling cascade inside the cell. Activated insulin 
receptor promotes phosphorylation of insulin receptor substrate (IRS) and its 
recruitment to the cell membrane, which is needed for recruitment and 
activation of phosphatidylinositol 3-phosphate kinase (PI3K). In the cell 
membrane PI3K bound to IRS adds an additional phosphate group on its 
substrate phosphatidylinositol-4,5-phosphate (PIP2) to produce 
phosphatidylinositol-3,4,5-phosphate (PIP3). PIP3 is a signaling molecule, 
which is recognized by a special protein domain called PH (for Pleckstrin 
Homology) domain. The concentration of PIP3 is controlled by PI3K and 
PTEN – a phosphatase that antagonizes PI3K activity by removing a 
phosphate from PIP3.  
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Figure 1 Model of mammalian TOR signaling 
Two distinct mTOR complexes exist in the cell. Rapamycin-sensitive mTOR 
complex 1 controls cell growth and size through regulation of a variety of 
indicated processes and rapamycin insensitive mTOR complex 2, which is 
thought to control cell shape. mTORC1 is integrating inputs from growth 
factors/Insulin, nutrients and energy status, while factors regulating mTORC2 
are largely unknown (see text for details). Grey arrows indicate activation, red 
bars – inhibition.  
 
PIP3 production triggers translocation to the cell membrane of PDK1 
(phosphoinositide-dependent protein kinase 1) and AKT kinase (also 
designated as PKB – Protein Kinase B), both of which possess PH domains. 
Colocalization at the membrane allows efficient activation of AKT by PDK1 by 
phosphorylation on the so-called activation loop. AKT is a very important 
cellular kinase and links insulin and TOR signaling through TSC1/2 complex 
and Rheb (Hay and Sonenberg, 2004).  
Tuberous sclerosis proteins TSC1 (hamartin) and TSC2 (tuberin) act as a 
heterodimer that negatively regulates mTOR signaling by inactivating Rheb 
(Ras homolog enriched in the brain). TSC complex act as a GTPase 
Activating Protein (GAP) of Rheb, promoting GTP hydrolysis by Rheb and 
thus its inactivation. TSC2 is phosphorylated and functionally inactivated by 
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AKT in response to insulin. Rheb can bind and activate TORC1 although the 
precise mechanism remains elusive (Long et al., 2005a; Manning, 2004).  
TSC complex is a component where additional inputs into TOR signaling feed 
in, such as energy status and stress. TSC2 is positively regulated by AMP-
activated protein kinase (AMPK). AMPK is activated in response to low 
cellular energy (high AMP/ATP ratio) and downregulates mTORC1 activity 
through TSC complex (Inoki et al., 2003). This couples energy status with 
protein synthesis, ribosome biogenesis and growth – all energy dependent 
processes. Other kinds of stress, such as hypoxia and DNA damage have 
been implicated in deactivation of mTORC1 activity by TSC stimulation 
(Brugarolas et al., 2004; Feng et al., 2005; Reiling and Hafen, 2004). 
 
Other regulators working through TSC complex 
Additionally, TSC2 can be phosphorylated by other kinases activated by 
growth factors, such as ERK2 (Ma et al., 2005) and its downstream kinase 
RSK (Roux et al., 2004) and also p38 activated kinase MK2 (Li et al., 2003). 
ERK and p38 kinases are part of the MAP (Mitogen-activated Kinase) 
signaling pathway, implying that it may have cross-talk with TOR (for further 
detail, see the introduction to MAP4K3 function in Drosophila). The 
phosphorylation sites of MAP kinases are different from those of AKT and are 
not conserved in Drosophila, while AKT’s phosphorylation sites are. Although 
it is clear that TSC complex is a central regulator of TORC1, our 
understanding of all the inputs going through this node and their relative 
importance is still far from complete. There is an urgent need to develop new 
tools that would complement existing biochemical and genetic methods to 
unveil the complex regulatory circuits controlling TOR signaling. During my 
PhD I worked toward developing such a tool: a fluorescence based probe to 
assess mTOR activity in cells. 
 
Nutrients regulation of TOR 
TORC1 is regulated by nutrients, especially amino acids. Starvation of amino 
acids leads to rapid dephosphorylation of TORC1 substrates, and is reversed 
by re-addition of amino acids. In physiological terms this makes perfect sense 
– sensing amino acids is necessary for protein production since amino acids 
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are the building blocks for proteins. Although nutrient sensing is the most 
conserved function of TORC1, it is still poorly understood. Reports vary as to 
whether any of the classical upstream regulators of TOR are involved. The 
emerging consensus is that TSC complex is not required for amino acid 
signaling to TOR, while Rheb is required, although it is not clear whether it is 
actively participating or just needs to be present in the cell. Budding yeast S. 
cerevisiae lack functional orthologs of TSC and Rheb, while still being 
sensitive to amino acids, suggesting that amino acids can signal directly to 
TORC1. 
Is has recently been proposed that some newly discovered proteins such as 
hVps34 and MAP4K3 mediate the amino acid stimulation of mTORC1 (Byfield 
et al., 2005; Findlay et al., 2007; Nobukuni et al., 2005). I will describe these 
findings in more detail in the introduction to the MAP4K3 in Drosophila. Since 
amino acid sensing by TOR is so poorly understood we decided to test the 
function of MAP4K3 – a new candidate gene for mediating amino acid 
signaling to TOR in the whole organism context, using Drosophila 
melanogaster as a model.   
1.4. Downstream of TOR – regulation of translation and 
growth  
 
TOR signaling regulates a stunning array of cellular functions. These include 
translation, ribosome biogenesis, marcoautophagy, transcription, metabolism, 
and actin organization (Bhaskar and Hay, 2007; Sarbassov et al., 2005; 
Wullschleger et al., 2006). How is TOR regulating all these cellular 
processes? To answer this we need to look at the substrates of TOR. There 
are surprisingly few substrates known for TOR and the best-characterized 
ones are those involved in control of translation. 4EBP1 and p70 S6K are 
commonly used as a readout of TORC1 activity.  
4EBP1 is a negative regulator of translation. Specifically, it can block 
translation initiation, the first step of protein synthesis. 4EBP1 stands for 
eIF4E binding protein1, a repressor of eukaryotic translation initiation factor 
4E (eIF4E). The 5’ end of nearly all mRNAs possesses a cap structure  
(m7GpppN, in which “m” represents a methyl group and “N”, any nucleotide) 
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that is specifically recognized and bound by eIF4E. The assembly of a 
ribosome on mRNA starts with eIF4E binding of the cap structure. eIF4E is a 
bridging element between the cap and another initiation factor, eIF4G. eIF4G 
is a large scaffold protein connecting eIF4E with the rest of the translation 
initiation machinery. 4EBP1 has an eIF4E binding motif similar to the one in 
eIF4G and is able to repress translation by binding eIF4E and thereby 
preventing it from association with eIF4G  as depicted in Figure 2A (Hay and 
Sonenberg, 2004; Proud, 2007).  
Mammals have three 4EBPs: 4EBP1, 4EBP2, and 4EBP3, encoded by three 
separate genes, whereas Drosophila expresses only one 4EBP. 4EBP1 is the 
best-studied one and its binding to eIF4E is regulated by phosphorylation via 
mTOR (Figure 2).  
 
  
 
Figure 2 4EBP1 binding to eIF4E is regulated by TORC1 mediated 
phosphorylation 
(A) When hypophosphorylated 4EBP1 is bound to eIF4E, translation is 
blocked. Upon mTOR activation, it is hyperphosphorylated and dissociates 
from eIF4E allowing the latter to interact with eIF4G and the rest of the 
translation initiation machinery to form eIF4F complex, necessary for efficient 
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translation. (B) 4EBP1 model showing important motifs and phosphorylation 
sites. Adapted from (Proud, 2007). 
The phosphorylation pattern of 4EBP1 is complex and not entirely clear. The 
following phosphorylation sites have been identified in 4EBP1: Thr37, Thr46, 
Ser65, Thr70, Ser83, Ser101, and Ser112 (residue numbers are for the 
human protein, subtract 1 for sites in rat and mouse). The first four are the 
most important and phosphorylation of these sites in cells occurs in an 
ordered fashion, with that of Thr37 and Thr46 occurring first, followed by 
Thr70, and finally Ser65. The sites on 4EBP1 differ in sensitivity to rapamycin 
treatment of cells: phosphorylation of Thr70 and Ser65 generally shows a 
greater decrease in response to rapamycin than does phosphorylation of 
Thr37 and Thr46 (Gingras et al., 2001; Mothe-Satney et al., 2000). Two motifs 
in 4EBP1 are essential for the efficient phosphorylation in cells. The first is a 
TOS (target of rapamycin signaling) motif formed by the last five C-terminal 
amino acids, Phe-Glu-Met-Asp-Ile. TOS motif is thought to bind to raptor, 
which supposedly mediates substrate specificity of TORC1, and is needed for 
phosphorylation of Ser65 and Thr70. Phosphorylation of Thr37/Thr46 does 
not require the TOS motif, but depends instead on an N-terminal RAIP (Arg-
Ala-Ile-Pro) motif (Proud, 2007; Tee and Proud, 2002; Wang et al., 2005). 
The complex hierarchical phosphorylation of 4E-BP1 and its dependence on 
two distinct motifs leads one to question whether all the mTOR-regulated sites 
in 4E-BP1 and S6K1 are really direct targets for phosphorylation by mTOR 
itself.  
S6K1, a ribosomal protein S6 (rpS6) kinase, is another “classical” TORC1 
substrate. Rapamycin inhibits activation of S6K1 in response to insulin, and 
the drug reduces rpS6 phosphorylation in multiple cell types. S6K1 belongs to 
the AGC family of protein kinases and requires phosphorylation at two sites 
for its full activation, a site in a C-terminal hydrophobic motif and a site in the 
T loop of the kinase domain. mTORC1 mediates phosphorylation of Thr389 
within the hydrophobic motif, whereas PDK1 is responsible for 
phosphorylation of the T loop (Harris and Lawrence, 2003; Wullschleger et al., 
2006). Activated S6K phosphorylates rpS6 and thus promotes efficient 
translation through increased translation of a subset of mRNAs, although how 
it does so remains unclear. Importantly, when activated S6K can 
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phosphorylate IRS and attenuate signaling through the insulin pathway. This 
negative feedback loop has been proposed to play a role in the development 
of insulin resistance in diabetes and obesity. For instance, when mTORC1 is 
activated by high levels of nutrients, activated S6K is decreasing PI3K 
signaling by phosphorylating and inactivating IRS. 
Although much understanding has been gained regarding TOR signaling, 
present knowledge and understanding of this system remains insufficient to 
allow disruption of cancer and metabolic diseases. 
 
1.5. Metabolism regulation by Insulin/TOR pathway in 
Drosophila melanogaster 
 
Physiological significance of TOR signaling lies in its control of essential 
cellular functions – metabolism and growth. Dysregulaton of metabolism is 
associated with major human diseases such as diabetes, obesity, 
cardiovascular disease and some cancers (Baker and Thummel, 2007). The 
impact of these on human health is hard to overestimate and this drives large 
amount of interest and efforts into understanding the underlying mechanisms 
of metabolism regulation.  
Insulin is a key regulator of energy homeostasis. It is a systemic hormone that 
in mammals regulates the balance between dietary intake, storage and 
release of energetic currency of the body, carbohydrates and lipids, according 
to the organism’s needs. Upon food intake, glucose and other nutrients 
(amino acids, lipids) levels rise in the circulation and trigger insulin secretion 
from pancreas. Insulin, through activating of intracellular signaling cascade, 
elicits specific responses in different tissues of the organism to promote 
nutrient uptake and storage. Glucose is taken up mainly by the muscle and 
adipose tissues but also liver and other tissues. In the liver insulin is inhibiting 
glycogen breakdown and gluconeogenesis. When nutrients influx is low and 
energy needs are high, glucose levels fall and insulin goes down, while other 
hormones such as glucagon, adrenaline and corticosteroids promote hepatic 
glucose production (Rosen and Spiegelman, 2006).  
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Insulin signaling inside cells is responsible for execution of the response to 
insulin. When tissues responses to insulin are not efficient, this results in a 
state known as insulin resistance. Insulin resistance is manifested in high 
glucose levels and is one of the hallmarks of diabetes mellitus and obesity 
(Biddinger and Kahn, 2006).  
One of the tissues where insulin resistance produces significant problems for 
the organism is the adipose tissue. Adipose tissue is the main form of energy 
stores in the organism. It is closely connected with glucose homeostasis, too 
much fat (obesity) is associated with insulin resistance and hyperglycemia. 
Although fat tissue is only responsible for a fraction (10-15%) of glucose 
uptake from circulation, with most glucose being taken up by muscle (Kahn, 
1996), adipocytes can affect glucose levels by a number of endocrine and 
non-endocrine mechanisms (Rosen and Spiegelman, 2006). Insulin 
stimulates glucose transport, lypogenesis, fatty acids uptake and maturation 
of adipocytes. This is achieved by complex intracellular signaling cascades 
regulating existing proteins and also changes in translation and transcription. 
Under starvation, insulin activity is low and lipids in adipose tissue are 
mobilized to provide energy for organism’s activity.  
Insulin signaling is conserved in Drosophila and because it usually has less 
redundancy in various components of insulin signaling Drosophila is 
becoming increasingly popular model for metabolic studies (Baker and 
Thummel, 2007). Insect fat body is an organ that combines functions of 
mammalian liver and white adipose tissue; it stores glycogen and lipids which 
are mobilized in the times of need.  
Recent studies in flies established that Insulin-Like Peptides (ILPs) and 
Adipokinetic Hormone (AKH) analogs of mammalian insulin and glucagon, 
respectively, regulate carbohydrate and lipid homeostasis in a manner similar 
to mammalian systems, highlighting conservation of energy metabolism 
regulation in Drosophila (Brogiolo et al., 2001; Broughton et al., 2005; Kim 
and Rulifson, 2004; Lee and Park, 2004). Ablation of cells producing some of 
seven Drosophila ILPs results in diabetic-like phenotypes (Rulifson et al., 
2002). On the contrary, ablation of cell producing AKH results in decrease of 
circulating trehalose (main blood sugar in Drosophila), while ectopic AKH 
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expression in fat body leads to elevated trehalose and reduction of fat through 
increased lypolysis (Lee and Park, 2004).  
Insulin signaling activates an array of cellular effectors. One of the key 
effectors is PI3 kinase, which acts through at least two branches: 
transcriptional control via inactivation of transcriptional activator FOXO and 
control of translation and metabolism via TOR kinase (Baker and Thummel, 
2007). Reduction of insulin signaling in fat body genetically by inhibiting PI3K 
activity mimics starvation (Britton et al., 2002) and dTOR mutants exhibit 
morphology changes in fat body typical for starvation (Zhang et al., 2000). 
Numerous mutants connected to the Insulin/TOR pathway have metabolic 
phenotypes (Bohni et al., 1999; Colombani et al., 2003; Luong et al., 2006; 
Teleman et al., 2005a, b; Tsukiyama-Kohara et al., 2001; Um et al., 2004), 
establishing TOR signaling as a major conserved regulator of metabolism. 
Results from MAP4K3 mutant analysis presented in this thesis provide 
additional support to this function and add a link between nutrient sensing, 
metabolism and growth. 
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2. Aims of the Thesis 
In order to understand a complex biological system such as TOR signaling we 
need to achieve a number of goals. Firstly, to identify all functional 
components that constitute the underlying physical framework of the 
interacting proteins. Secondly, to decipher the nature of interactions between 
the individual components and regulatory modules that they constitute, such 
as protein complexes composition and function of the individual proteins in the 
complex (enzyme-substrate, activator-effector, etc.) Thirdly, we need to 
understand the regulation and biological function at the whole system level, 
including dynamics of activation and inhibition, relative importance of different 
inputs, crucial components and information flow through the network 
(amplification vs. attenuation, linear vs. circuitry, etc.) 
My thesis aims at contributing to this task using three different approaches to 
generate new tools and characterize novel components of TOR signaling. The 
first goal was to develop a tool that would visualize mTORC1 signaling in live 
cells. Based on recent successes of in vivo fluorescent labeling I aimed to 
develop a sensor for a cell culture assay that would allow monitoring of 
TORC1 activity in vivo, in a spatially and temporally resolved manner, a task 
impossible till now. There are several reasons why it would be useful to have 
a readout for TORC1 activity: (1) one method for identifying components of 
the pathway is to do RNAi screening in cells, however this requires a readout 
for TORC1 activity; (2) to study the dynamics of TORC1 pathway activation; 
and (3) to visualize TORC1 activation in vivo to see if there are any spatial 
patterns to its activation – one can assume it is not uniformly active in tissues, 
but depends on local nutrient level, oxygen levels, etc.. 
I then employed a classical genetic approach, using the advantages of 
Drosophila melanogaster as a model organism, to analyze the function of a 
newly identified component of TOR signaling on the whole organism level. 
Lastly, I utilized a chemical biology strategy to discover novel small molecule 
inhibitors for an important TOR dependent protein-protein interaction. This last 
project is still at the early phase, so I will not discuss it in this thesis, as this 
work will be followed and published later. 
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3. Development of a FRET-based probe for TOR 
signaling 
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3.1. Introduction - Flourescent probes as tools to 
visualize cellular processes 
 
3.1.1. Fluorescence and Fluorescence Resonance Energy 
Transfer phenomena 
 
Observation has been at the heart of biological sciences, especially since 
Antonie van Leeuwenhoek designed his first microscope in the 17th century. 
Microscopy has contributed enormously to our understanding of biology 
ranging from whole organism processes such as embryonic development, to 
the cellular level processes such as cell division, and down to the molecular 
level such as observing localization of labeled molecules within the cell. In 
modern biology proteins are typically labeled with fluorescent molecules. 
Fluorescence based methods enable visualization of signaling events in vivo 
and provide spatio-temporal information, which is critical for understanding 
signaling networks (Aoki et al., 2008; Miyawaki, 2003).  
Fluorescence is a physical phenomenon that results from ability of atoms and 
molecules to absorb light at a certain wavelength and to subsequently emit 
light of longer wavelength. This process is schematically illustrated by 
Jablonski diagram in Figure 3. It shows possible routes by which an excited 
molecule can return to its ground state via higher energy singlet and triplet 
states. A rapid return results in fluorescence and a delayed return results in 
phosphorescence. The time difference between excitation and emission is 
called the fluorescence lifetime. Although the entire molecular fluorescence 
lifetime, from excitation to emission, is measured in only billionths of a 
second, it can be measured using dedicated equipment. During its 
fluorescence lifetime an excited electron loses some energy due to collisions 
with surrounding molecules, called vibrational relaxation (non-radiative) until it 
reaches the lowest excited energy level from where it can return to the ground 
state by releasing the rest of the energy in the form of a photon (radiative). 
This photon has a longer wavelength (lower energy) than the excitation 
photon because some energy is lost due to non-radiative processes 
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(vibrational relaxation). The difference between excitation and emission 
wavelength is called Stokes-shift (Wolf, 2003). 
 
 
Figure 3 Jablonski diagram 
Fluorescence occurs when a molecule absorbs a quantum of light and an 
electron goes to from ground state to one of the excited states. A return from 
the higher energy state can occur via fluorescence with emission of a photon. 
Alternatively, an intersystem crossing to a triplet state can occur and electrons 
return to the ground state by phosphorescence. Part of the energy is lost in a 
non-radiative way, through vibrational relaxation. 
 
In large molecules with many electrons and many nuclei there are many 
vibrational levels which causes their excitation and emission spectra to seem 
continuous rather than consisting of the sharp bands observed in atomic 
spectra.  
Instead of the returning to the ground state and radiating a photon, an excited 
electron can transfer the energy non-radiatively to a neighboring molecule, if 
certain criteria are met. This phenomenon was first described by Förster and 
hence it is called Förster (or Fluorescence) Resonance Energy Transfer 
(FRET) (Förster, 1948). FRET is based on a long range dipole-dipole 
interaction which are limited to distances up to 10 nm (100 Å). This is the 
scale on which many biological interactions take place, which was the reason 
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for the renewed interest in this photo-physical phenomenon, which was 
previously used as a “spectroscopic ruler” (Stryer, 1978). For resonance 
energy transfer to occur, three specific conditions must be met. (1) The 
emission spectrum of the fluorophore, also called the donor, must overlap the 
acceptor molecule’s (which is usually also a fluorophore) absorbance 
spectrum. (2) The emission dipole of the donor and the absorption dipole of 
the acceptor must not be oriented perpendicular to each other. If the emission 
dipole of the donor is perpendicular to the absorption dipole of the acceptor, 
there will be no FRET. (3) Donor and acceptor molecules must reside within 
10 nm (100 Å) of each other. Förster showed that the efficiency of resonance 
energy transfer, or FRET efficiency (the fraction of the photon energy 
absorbed by a fluorescent molecule that is transferred to an acceptor through 
dipole-dipole interactions), has a sixth power dependence on the distance 
between the donor and the acceptor as described by an equation: 
 (Eq.1) 
where E is FRET efficiency, R0 is the Förster Radius and r  is the distance 
between the fluorophores. Because of such strong dependence of the 
efficiency on the distance, FRET is very sensitive to a change in a distance 
between donor and acceptor. For example, doubling of the distance reduces 
the transfer rate 64 times. The Förster Radius, R0, summarizes other factors 
influencing the transfer rate such as the effect of the solvent, relative 
orientations of the transition dipoles and a degree of overlap between the 
emission spectrum of the donor and excitation spectrum of the acceptor. 
FRET is maximal when donor emission and acceptor excitation dipoles are 
parallel to each other. For a mixture of molecules with random relative 
orientations due to rotation diffusion factor k=2/3 is usually assumed. From 
Eq.1 Förster Radius is the distance at which half of the energy is transferred 
to the donor.  
3.1.2. Determination of FRET 
 
Many different methods have been developed or proposed for determining 
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FRET efficiency, some of them theoretically quite complex and requiring 
special instrumentation (Jares-Erijman and Jovin, 2003; Sekar and 
Periasamy, 2003). The methods for measuring FRET can be divided by the 
principle into 3 groups: (i) methods that measure changes in donor 
fluorescence; (ii) methods that monitor changes in acceptor fluorescence; 
(iii) methods that use the orientation of the fluorophores as a readout for 
FRET. Each one of those has its advantages and disadvantages and I will 
describe the most common ones. 
Methods that monitor donor fluorescence are very popular and include 
acceptor photobleaching and fluorescent lifetime imaging (FLIM). They 
compare donor intensity (acceptor photobleaching) or lifetime (FLIM) in the 
presence or absence of the acceptor. As the acceptor is quenching donor 
fluorescence or decreasing the donor’s fluorescent lifetime due to FRET 
one can calculate FRET efficiency by comparing samples with and without 
the donor. Acceptor photobleaching is a straightforward approach in which 
the sample is illuminated with strong light or a laser that leads toward 
photo-destruction of the acceptor, and donor fluorescence intensity is 
compared before and after bleaching. This method is easy to implement on 
both wide-field and confocal microscopes but it is not suitable for time-
lapse experiments as the donor is destroyed. Care should be taken to make 
sure that no fluorophore movement occurs during the bleaching process, 
which can take some time; this is especially difficult to achieve in live 
samples.  
FLIM is a method that measures FRET by monitoring changes in a donor’s 
fluorescent lifetime, that is, how rapidly a population of fluorophores emits 
light after a short excitation pulse, the fluorescent lifetime of a donor should 
become shorter if FRET is occurring (Lakowicz et al., 1992). FLIM requires 
some specialized instrumentation that is not available in most laboratories. 
The advantage of measuring the fluorescence lifetime of chromophores is 
that this parameter is directly dependent upon excited-state reactions but 
independent of chromophore concentration and light-path length, conditions 
that are difficult to control inside a cell (Bastiaens and Squire, 1999). 
The sensitized emission method for measuring FRET involves monitoring 
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acceptor emission as a result of donor excitation. This seems to be the 
most straightforward method of measuring FRET but has caveats in 
practice. The emission spectra of most fluorophores have long tails towards 
longer wavelengths, which makes it difficult to separate donor and acceptor 
emission completely (bleed-through). The contribution of the donor 
emission to the sensitized emission channel has to be experimentally 
determined and corrected for in the evaluation of the data (unmixing). In 
addition, excitation wavelengths that are used to excite donors can excite 
acceptors in some cases, which also needs to be corrected for. Using this 
method, intensity calculated in the corrected FRET image not only encodes 
information about the amount of FRET in the sample, but also depends of 
the amount of sample present, the excitation intensity, the excitation 
wavelength, and the instrumentation used (filters, objectives, detectors, 
etc.). Thus, the FRET signal measured is not typically comparable to that 
obtained in experiments conducted on other microscopes or even to other 
experiments on the same microscope with different samples or parameters 
used.  
One simplified method that does not calculate absolute FRET efficiency but 
detects relative change in FRET is measuring the ratio of acceptor-donor 
fluorescence, so called ratiometric FRET measurement (Wouters et al., 
2001). It is applicable for cases where there is a constant stochiometry 
between donor and acceptor molecules as in the case where both donor 
and acceptor fluorophores are on the same molecule (Adams et al., 1991; 
Miyawaki et al., 1997). 
Measuring FRET by fluorescent polarization microscopy compares the 
orientation of the molecules excited (by linearly polarized light) with the 
orientation of the molecules that emit fluorescence (in response to 
excitation). Since fluorescent lifetimes are usually much shorter than 
rotation times in solution, especially for slow-moving fluorophores such as 
fluorescent proteins, in the absence of FRET, the molecule excited is the 
molecule emitting fluorescence, and thus its orientation will be highly 
correlated. If FRET occurs, the molecule excited may be different from the 
molecule emitting, and thus the correlation between their orientations will 
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decrease substantially (Rizzo and Piston, 2005). This method is relatively 
new and still needs to be fully established.  
There is no one perfect method for FRET determination and they all suffer 
from certain assumptions and technical limitations. One must choose a 
single method based one the specifics of the experimental system and 
available instruments and it is advisable to employ several different 
methods to validate each other. 
3.1.3. Green Fluorescent Protein and its variants for in vivo 
labeling 
 
FRET’s renewed popularity in the last decades stems from two factors. Firstly, 
the wealth of biochemical data from various protein-protein interaction 
methods (yeast two-hybrid, cell extract pull-down assay, and 
immunostanings) needs to be confirmed in vivo. Secondly, at the same time in 
vivo fluorescent labeling using genetically encoded Fluorescent Proteins (FP) 
has been developed and provides the tools for in vivo technology. 
The first fluorescent protein, later termed GFP (Green Fluorescent Protein) 
was purified from a jellyfish Aequorea Victoria 1962 by Shimomura et al 
(Shimomura et al., 1962). It took over 30 years until the gene encoding GFP 
was introduced and expressed in other organisms such as E.coli and 
C.elegans (Chalfie et al., 1994). Later Roger Tsien and his lab contributed to 
our understanding of the chemistry of the fluorescence properties of GFP. He 
has made extensive contributions to the development of GFP variants with 
fluorescence emission in the whole visible spectrum, with increased 
brightness and photostability and improved folding properties along with rapid 
maturation of their chromophores (Heim et al., 1995; Heim et al., 1994; Heim 
and Tsien, 1996; Tsien, 1998).  
Notably, this year the impact of GFP discovery and characterization was 
acknowledged by awarding Shimomura, Chalfie and Tsien a Nobel prize 
(http://nobelprize.org/nobel_prizes/chemistry/laureates/2008/index.html). 
GFP is a 238 amino acid protein (Prasher et al., 1992). Residues 65-67 (Ser-
Tyr-Gly) in the GFP sequence spontaneously form the fluorescent 
chromophore, which is located inside the beta-barrel structure of the protein  
as depicted in Figure 4 (Brejc et al., 1997) 
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Figure 4 Ribbon diagram of the wtGFP structure  
The α-helices are shown in red, the β-strands are shown in green, and the 
chromophore is shown as a ball-and-stick model (adapted from Brejc et al., 
1997). 
 
The fluorophore forms post-translationally in a  oxygen-dependent cyclization  
reaction. Since no other cellular factors are needed GFP can be expressed in 
any aerobic cell or organism. 
Original wild-type GFP was greatly improved by mutagenesis to make it 
brighter, more photostable, less sensitive to environment (such as pH and ion 
concentration). Fast folding of the protein and fluorophore maturation was 
also achieved. In addition many spectral variants of GFP with shifted 
excitation/emission maxima have been developed to enable labeling of 
cellular components with different colors (Chudakov et al., 2005). A commonly 
used red-shifted variant is EYFP (Enhanced Yellow Fluorescent Protein), 
which contains the mutation T203Y. The excitation peak is shifted to 512 nm 
and the emission to 525 nm. Additional mutations in the periphery of the 
fluorophore increase the extinction coefficient (V68L) and accelerate folding 
(S72A) (Ormo et al., 1996). Another EYFP variant called Citrine has increased 
photostability and decreased pH and chlorine sensitivity (Griesbeck et al., 
2001). Further mutations at the fluorophore or surrounding region have 
created several more colors based on the wtGFP. Cyan fluorescent protein 
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(ECFP) is a blue-shifted variant, which has an excitation maximum at 434 nm 
and an emission maximum at 475 nm (Heim and Tsien, 1996) and is the most 
commonly used variant together with EYFP as a FRET pair. Recently other 
naturally fluorescent proteins have been described from various marine 
organisms, in the search for more options in the red part of the spectrum. 
Other advances include development of photoactivatable and photoswitchable 
FPs to provide maximum flexibility and control (Chudakov et al., 2005; Shaner 
et al., 2007). 
For FRET applications, the donor-acceptor pair should ideally fulfill several 
criteria: The donor should have a large quantum yield (the ratio of the number 
of photons emitted to the number absorbed), the spectral overlap should be 
as large as possible and the donor should have a large stokes shift to allow a 
selective excitation of the donor. ECFP-EYFP (or Citrine) is a well-
characterized pair that has been used extensively and this is the reason it was 
used in this thesis. wtGFP and all its derivates have a weak tendency to 
dimerise, which may interfere with the performance of FRET probes. To solve 
the potential problem stemming from dimerization so called “monomeric” 
versions of GFP variants have been created, in which residue 206 has been 
mutated from Ala to Lys (Zacharias et al., 2002). However, it has even been 
shown that in some cases this dimerization property can contribute to the 
performance of the probe (Jost et al., 2008). Therefore, it must be determined 
experimentally whether monomeric or wt variants perform better. A list of 
selected GFP variants used in this thesis is presented in Table 1.1. 
 
Table 1.1 GFP-variants compared to the wt-GFP 
.  
 
 
 
 
 
 
 
 
 
 
 
Note that wt-GFP has two excitation peaks. 
Name Excitation [nm] Emission [nm] 
wt-GFP 
 
395 
472 
504 
GFP2 396 510 
ECFP 433 475 
EYFP 514 527 
Citrine 516 529 
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3.1.4. Design and uses of FRET probes 
 
The main advantage of the FRET technology is the ability to visualize 
biochemistry in vivo in space and time. FRET probes have been developed to 
visualize many different processes in the cell, from Ca++ concentration 
fluctuations to membrane receptor activation during growth (Wouters et al., 
2001). The design of FRET probes is limited only by the imagination of the 
researchers and many creative approaches have been employed. FRET 
probes based on GFP variants can generally be classified in two groups. The 
first group is intermolecular FRET probes, where donor and acceptor are on a 
separate molecules, genetically fused to proteins (domains) of interest, that 
are able to interact with each other. Upon binding of two interacting partners, 
donor and acceptor come to proximity allowing FRET. The second group 
includes intramolecular FRET probes, where both donor and acceptor are part 
of the same molecule. Usually one or more domains can change conformation 
to separate or juxtapose the probes. In response to the binding of a particular 
ligand, or upon specific modification, the intramolecular interaction of domains 
leads to a change in the spatial orientation and distance between the FPs, 
resulting in visible changes in the FRET effect.  The interacting domains can 
be both sandwiched between donor and acceptor, or one may be on a 
separate molecule that binds its partner under specific conditions (for 
instance, when phosphorylated). These basic designs are illustrated in Figure 
5. 
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Figure 5 Structure of FRET probes 
Domain X binds domain Y, when it is phosphorylated – pY. Possible designs 
of FRET probes are presented: (A) Intermolecular FRET probe (B) 
Intramolecular FRET probe (C) Intramolecular FRET probe, wher only domain 
X is part of the probe and Y is not. Note that in (C) binding results in loss of 
FRET as opposed to (A) and (B). Modified from (Kurokawa et al., 2004). 
 
Intramolecular FRET probes became popular following successful 
demonstration of this approach in Ca2+ signaling (Miyawaki et al., 1997). Many 
different probes, monitoring tyrosine and serine/threonine kinase activities, 
small GTPases and intracellular second messengers (lipids, ions, etc) have 
been developed (see (Aoki et al., 2008) for the full list). These so called 
conformational FRET probes have a number of advantages. They have a 
stochiometrically stable ratio of donor and acceptor and thus allow simple 
acceptor/donor intensity ratio representing FRET efficiency, without 
complicated correction factors. Additionally if both domains are on the same 
molecule, their local concentrations are very high and they can find each other 
easily, increasing FRET efficiency. Moreover, pertubation of endogenous 
signaling is also lower than in other designs, since the domain will 
predominantly react intramolecularly without interfering with endogenous 
components. The disadvantage of intramolecular FRET probes are that it is 
 32 
difficult to design a well-functioning probe, since the magnitude of change is 
usually not large. 
Intermolecular FRET probes are easy to make and usually have a better 
signal/noise ration since there is no “baseline” FRET when the proteins are 
not bound. On the other hand, since the concentration of the donor and 
acceptor are not known, one must perform spectral corrections for measuring 
FRET, which makes the experiments and analysis more complicated and 
creates room for errors. In addition there is a greater chance that fusions of 
donor and acceptor will interact and perturb endogenous signaling processes, 
especially when overexpressed. 
Although FRET is becoming more and more popular to study protein-protein 
interactions in vivo, many articles have debated about the best way to detect it 
and warned of numerous caveats in interpreting the results (Berney and 
Danuser, 2003; Piston and Kremers, 2007; Vogel et al., 2006). Several 
general limitations are well known for FRET approaches.  Sensitivity or 
dynamic range is usually low, especially for intramolecular FRET probes. 
There is no way to predict the efficiency of FRET and to achieve a satisfactory 
FRET probe may require extensive optimization to achieve a signal that can 
be reliably detected above the background noise level (Hires et al., 2008). 
FRET efficiency typically lies within tens of percents, rarely reaching 50% in 
best probes (Berney and Danuser, 2003; Kurokawa et al., 2004). This limits 
applicability of these probes in systems where small changes have to be 
measured reliably and also as readout for High Throughput Screening (HTS), 
where high signal/noise ratio is required.  Perturbation of endogenous 
signaling by introducing artificial components, capable of interacting or 
competing with cellular signaling is always a concern. Integrity of the probes 
in the cell can also be an issue. Due to different efficiencies of folding, 
maturation and proteolysis, different species of the incomplete or non-
fluorescent probe can co-exist within the cell, attenuating the signal or 
increasing the background (Miyawaki, 2003). 
Despite many limitations, FRET remains probably the best approach to 
visualize protein-protein interactions in living cells. Researchers have to be 
aware of them and interpret the results cautiously with consideration of 
possible caveats, such as dynamics of acceptor abundance, random FRET, 
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and donor-acceptor stoichiometry. Universal use of proper controls and 
standards should improve the comparability of results from different 
laboratories. 
 
3.1.5. FlAsH labeling 
 
One of the known drawbacks of GFP-variants’ fusions is that the resulting 
chimeric protein is altered in a way that disrupts its biological function. 
Although in many cases the biological function is preserved, because of the 
modular structure of proteins, sometimes relatively the large GFP domain 
(~25 Kd) can cause steric obstruction and affect the protein structure of 
regulation (Vilardaga et al., 2003). Therefore small fluorescent tags are highly 
desirable for labeling proteins. 
FlAsH (Fluorescein Arsenical Hairpin binder) technology utilizes a small 
tetracystein motif to label proteins in cells. This approach was also pioneered 
by the Tsien lab (Griffin et al., 1998). Arsenoxides are known to have a high 
affinity for thiols, including closely spaced cysteines. FlAsH, containing two 
arsenoxides, has a high affinity for four appropriately spaced cysteines. The 
rigid spacing of the two arsenoxides enables FlAsH to bind with high 
specificity to the small tetracysteine motif introduced into proteins (Figure 6). 
The optimized tetracysteine motif has the 12 amino acids FLNCCPGCCMEP 
and binds FlAsH with high affinity.   
 
Figure 6 FlAsH labeling and comparison to GFP 
(A) Non-fluorescent FlAsH-EDT2 becomes fluorescent upon binding to the 
tetracystein motif, introduced into the protein of interest. (B) Size comparison 
of FlAsH-EDT2  with GFP domain. Much smaller size is an advantage as it is 
less likely to affect protein function. Modified from (Hoffmann et al., 2005). 
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A useful property of FlAsH is that the molecule becomes fluorescent only 
upon binding to the tetracysteine motif, so that only labeled protein produces 
fluorescent signal.  FlAsH is added to the cells as FlAsH-EDT2 adduct, to 
protect reactive arsenicals. However, it can bind to cysteins on other 
proteins in the cell, producing significant background staining (Stroffekova et 
al., 2001). 
When attached to a protein FlAsH has an excitation peak at 508 nm and 
emission peak at 528 nm, which makes it a good FRET acceptor for CFP. 
FlAsH was successfully used together with CFP as a FRET pair to monitor 
G-protein coupled receptor dynamics (Hoffmann et al., 2005) and in a 
protein kinase C FRET probe (Jost et al., 2008). 
This prompted me to try a FlAsH approach for making a TOR kinase FRET 
probe to overcome the difficulties of GFP-fusions as FRET probes. 
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3.2. Results 
3.2.1. Conformational FRET probe strategy 
 
Developing FRET-based probe for TOR kinase started with choosing a 
strategy, as there were several options available. First we decided which 
protein would be used as a basis for the probe and then what kind of probe to 
do. We chose 4EBP1 as one of the best studied substrates of TOR. Upon 
stimulation with insulin TOR phosphorylates 4EBP1 on multiple sites (some 
are phosphorylated directly by TOR and others are TOR dependant) causing 
4EBP1 to decrease its affinity to eIF4E (Gingras et al., 1999). Phosphorylated 
4EBP1 dissociates from eIF4E and thus allows efficient translation. 4EBP1 
has no defined structure in solution but upon binding to eIF4E at least part of 
it becomes structured as it has to adopt a structure supporting interaction with 
eIF4E (Marcotrigiano et al., 1999). This prompted us to try to make a 
conformational FRET probe based on 4EBP1. Conformational FRET probes 
exploit the changes in the 3D structure of a protein; by placing donor and 
acceptor fluorophores on a protein in such a way that their distance from each 
other, and hence FRET efficiency, will change upon a change in protein 
conformation. Conformational FRET probes have a number of advantages 
over other FRET probe designs, in particular that by hanging both donor and 
acceptor on one protein, the stochiometry, and thus relative concentration of 
the two is fixed, allowing FRET monitoring by a ratio of accetor/donor 
fluorescence upon donor excitation. Therefore, we decided on a 
conformational FRET probe attaching ECFP as a donor and Citrine as an 
acceptor to the ends of 4EBP1. 
The domain composition of our conformational FRET probe based on 4EBP1 
is depicted in Figure 7A. In the dephosphorylated state, the conformational 
FRET probe based on 4EBP1 is expected to bind to eIF4E and adopt a 
structured conformation. Since we don’t know how this structured 
conformation will affect the distance between the two fluorophores, we don’t 
know whether to expect a decrease or an increase in FRET relative to the 
unstructured state. Based on the structure of a 4EBP1 peptide bound to 
eIF4E, which adopts extended L-shape conformation I would expect that the 
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two fluorophores will be separated further from each other than in solution 
when unbound 4EBP1 exists as a random coil. As GFP variants have an 
intrinsic tendency to dimerization, they would probably associate with each 
other leading to more FRET. This scenario, where free 4EBP1 probe shows 
more FRET than bound is depicted in Figure 7B. 
 
 
Figure 7 Schematic of a conformational ECFP-4EBP1-Citrine FRET 
probe 
(A) Domain structure of the ECFP-4EBP1-Citrine FRET probe. P denotes 4 
main phosphorylation sites on 4EBP1. 
(B) Hypothetical model for conformational change induced by binding to 
eIF4E. Unphosphorylated probe is bound to eIF4E with donor and acceptor 
separated by a partially structured 4EBP1. Upon phosphorylation by mTOR, 
binding is lost and 4EBP1 adopts random coil conformation, which allows two 
fluorophores to come close together, leading to FRET. 
 
Initially I tried to work with the Drosophila 4EBP ortholog to work in the S2 
(Schneider’s 2) cells but because S2 cells are very small, poorly adherent and 
because most of the literature of 4EBP is about the mammalian cells we 
decided to switch to the mammalian system. We started with HEK 293 cells 
as these are readily transfected and have been used for studying the TOR 
 37 
pathway before, meaning that they have all the necessary components of the 
Insulin/TOR pathway. 
Figure 8 shows regulation of endogenous 4EBP1 in HEK 293 cells. 4EBP1 
was detected with the antibody against the total protein migrates in several 
distinct bands, which correspond to differently phosphorylated protein 
species. Dephosphorylated 4EBP1 is in the first lane after overnight serum 
starvation runs as a double band. Insulin stimulation, which activates TOR 
kinase, leads to phosphorylation of 4EBP1 and a shift up in its electrophoretic 
mobility. Treatment with PBS to deprive cells of amino acids and thus 
inactivate TOR or addition of Rapamycin to specifically inhibit TOR, leads to 
further dephosphorylation, which is not very clear from the lysate blot but is 
evident from the phosphospecific antibodies in Figure 8B. 
 
 
Figure 8 Regulation of endogenous 4EBP1 in HEK 293 cells 
Cells were starved of serum for 16 hours and treated with 1mg/ml Insulin, 
100nM Rapamycin or incubated in PBS for 30 min as indicated. Cell lysate or 
cap-beads bound fraction was analyzed by Western blot with total (A) or 
phosphospecific (B) 4EBP1 antibodies. 
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Both Rapamycin and PBS treatment decrease phosphorylation of 4EBP1 on 
Thr37/46 and Ser65 with PBS having a stronger effect. The functional 
significance of 4EBP1 phosphorylation is assessed by a Cap pull-down assay, 
where lysate is incubated with beads conjugated with m7GTP cap structure. 
This structure is recognized and bound by eIF4E and if it is bound by 4EBP1 
the whole complex is pulled down. Insulin stimulation almost completely 
abolishes binding, while both PBS and Rapamycin increase the amount of 
4EBP1 that is bound to eIF4E.  
Human 4EBP1 was amplified by PCR and inserted into the pCDNA3 vector 
between ECFP and Citrine. This ECFP-4EBP1-Citrine FRET probe had to be 
tested to make sure that it still retains the physiological regulation of 4EBP1 
and thus can faithfully reflect TOR activity. In HEK293 cells ECFP-4EBP1-
Citrine FRET probe phosphorylation was increased by insulin and decreased 
by PBS treatment on both Thr37/46 and Ser65 in a manner similar to the 
endogenous 4EBP1 (Figure 9B). This suggests that it is still recognized by 
mTOR and the PP2A phosphatase. Unfortunately binding to eIF4E was 
impaired and no longer regulated by insulin and PBS. Insulin did not decrease 
the amount of ECFP-4EBP1-Citrine in the cap pull-down and after PBS 
treatment we actually observed less ECFP-4EBP1-Citrine bound to eIF4E, 
which is contrary to expectations (Figure 9A). One possible explanation for 
this could be that if the amount of eIF4E in the cell is limiting and if 
endogenous 4EBP1 binds eIF4E better than the FRET probe, then binding of 
the FRET probe would be impaired. To overcome this potential problem, I 
contranstected eIF4E together with ECFP-4EBP1-Citrine using the same 
promoter in order to provide similar amounts of eIF4E. This solved the 
problem of competition with endogenous 4EBP1 (compare lanes 6 and 9) but 
binding of ECFP-4EBP1-Citrine was still constitutive and not regulated by 
Insulin or PBS (lanes 7-9).  
Constitutive binding of the conformational FRET probe was a discouraging 
result but the possibility still existed that phosphorylation alone would change 
the conformation of 4EBP1 and lead to a change in FRET.  It is known that 
sometimes a single phosphate group can lead to a significant change in a 
 39 
protein structure and to a change in FRET (Nagai et al., 2000), although this 
is usually the case for proteins with a well defined structure. 
 
 
Figure 9 Regulation of ECFP-4EBP1-Citrine in HEK 293 cells 
Cells were transfected with ECFP-4EBP1-Citrine alone or contransfected with 
eIF4E, after 24 hours starved of serum for 16 hours and treated with 1mg/ml 
Insulin or incubated in PBS for 30 min. Cell lysate or cap-beads bound 
fraction was analyzed by Western blot with anti-GFP (A) or phosphospecific 
4EBP1 (B) antibodies. 
In order to test if phosphorylation can change FRET for ECFP-4EBP1-Citrine 
probe I performed ratiometric measurement of FRET, using a widefield 
automated microscope. Figure 10 shows a representative panel of FRET 
measurements, measured as a ratio of Citrine/ECFP. Insulin was added to the 
cells to stimulate Insulin/mTOR pathway and to promote 4EBP1 
phosphorylation. After that, Rapamycin was added to inhibit mTOR and 
promote dephosphorylation. There was no consistent change in the 
Citrine/ECFP ration in response to either stimulation or inhibition of mTOR 
kinase. This could indicate that there is no change in the relative position of 
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the fluorophores following phosphorylation/dephosphorylation  of 4EBP1 or 
that the change is so small that it is not detectable by the method that I 
employed.  
 
 
Figure 10 Ratiometric FRET measurement of the ECFP-4EBP1-Citrine 
sensor in HEK 293 cells 
Cells were starved of serum for 16 hours and imaged under the widefield 
microscope. Following excitation of the ECFP, ECFP (donor) and Citrine 
(acceptor) emissions were captured and after subtraction of the background 
Citrine/ECFP ratio was calculated. At indicated times 1mg/ml Insulin or 2µM 
Rapamycin was added. Each color represents a single cell. 
One possible problem is that high levels of expression of the FRET probe are 
higher than physiological capacity of the cells to regulate it. Then only a small 
fraction of the FRET probe is phosphorylated, binding and even if it has a 
change in FRET, this change is masked by a much larger fraction of non-
regulated pool pf FRET probe molecules. To try to overcome this, I selected 
stable cell lines with low level of fluorescence hoping to get the FRET probe 
expression to more physiological levels. Figure 11 shows an example of 
response to insulin stimulation of the stable HEK293 cells. Addition of Hepes 
buffer as a control or Rapamycin didn’t change the FRET ratio, while addition 
of insulin resulted in a decrease of the Citrine/ECFP ratio. Rapamycin 
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pretreatment of the cells 10 min before insulin addition was not able to block 
the decrease as would be expected if the response was dependent on the 
mTOR kinase. It is noteworthy that the signal to noise ratio was not very good 
for the stable cells, as is evident from “jumps” in the graphs, while no 
manipulation was done. This most likely stems from the fact that the signal is 
low, since the cells were selected for their low expression levels.  
 
Figure 11 Ratiometric FRET measurement of the ECFP-4EBP1-Citrine 
sensor in stable HEK 293 cells 
Cells were starved of serum for 16 hours and imaged under the widefield 
microscope. Following excitation of the ECFP, ECFP (donor) and Citrine 
(acceptor) emissions were captured and after subtraction of the background 
Citrine/ECFP ratio was calculated. At the indicated time (vertical line) 30mM 
Hepes buffer, pH7.2, 1mg/ml Insulin or 100nM Rapamycin was added. For the 
Rapa, Insulin sample cells were pretreated with Rapamycin 10 min before 
Insulin treatment. Each graph represents average of 4-6 cells. 
Despite low signal/noise ratio, the response to insulin was reproducible and 
convincing but could not be blocked by either Rapamycin or Wortmannin, an 
inhibitor of PI3 Kinase (data not shown). This remained a mystery until a more 
careful analysis revealed that insulin addition changed the background 
fluorescence of the medium. This change was slight and came unnoticed in 
my initial analyses. I initially corrected background by calculating the mean 
value of the area without cells and subtracting it from all the images in the 
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time series for each channel, in a so called “global” background correction. 
This of course is only valid if the background remains stable throughout the 
entire experiment. Insulin for an unknown reason slightly changed the 
background fluorescence and the change was different for the donor and 
acceptor channel. Given that the signal from the cells was not very strong this 
background change led to a visible drop in the Citrine/ECFP ratio. After I 
determined what was causing the artifact of FRET ratio decrease, I started to 
correct each image in the time series using the “local” background from the 
same image, which eliminated the artifact of insulin addition. After this proper 
background correction no significant change in FRET ratio was left, indicating 
that there was no FRET change upon phosphorylation of the probe. Figure 
12B shows an example of background correction. Left panel – global 
background correction, insulin addition artifact is apparent as a drop in the 
ratio. Right panel – local background correction, after correction no response 
to insulin is present. In conclusion stable HEK293 cells did not show a FRET 
response. 
In parallel another cell line was tested to determine whether cell line specific 
factors may influence 4EBP1 regulation and hence my FRET probe 
performance. I used HeLa cells that were better suited for microscopy in 
comparison to HEK293, which were weakly adherent and often detached. 
Figure 12A shows that in HeLa cells the ECFP-4EBP1-Citrine FRET probe is 
phosphorylated in the expected manner, namely insulin increases 
phosphorylation, which is blocked by Rapamycin and PBS treatment reduced 
the amount of phosphorylated protein. Moreover, in a cap pull-down there was 
a slight decrease in the amount of the bound ECFP-4EBP1-Citrine FRET 
probe after insulin stimulation, although PBS failed to increase the binding. 
Unfortunately, ECFP-4EBP1-Citrine FRET probe did not show response to 
insulin (except for the background artifact) in HeLa cells (representative 
example shown in Figure 12B).  
All these results taken together suggest that the binding of the ECFP-4EBP1-
Citrine FRET probe is affected in a way that does not allow regulation by 
Insulin/mTOR pathway. Although phosphorylation of the ECFP-4EBP1-Citrine 
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FRET probe is similar to the endogenous 4EBP1 it does not translate into 
detectable FRET signal.  
 
Figure 12 Biochemical analysis and  FRET measurement of the ECFP-
4EBP1-Citrine sensor in HeLa cells 
(A) Cells were transfected with ECFP-4EBP1-Citrine and eIF4E, after 24 
hours starved of serum for 16 hours and treated with 1mg/ml Insulin or 
incubated in PBS for 30 min, where indicated, pretreated for 30 min with 
100nM Rapamycin. Cell lysate or cap-beads bound fraction was analyzed by 
Western blot with indicated antibodies. 
(B) Cells were starved of serum for 16 hours and imaged under the widefield 
microscope. Following excitation of the ECFP, ECFP (donor) and Citrine 
(acceptor) emissions were captured and Citrine/ECFP ratio was calculated. 
Left panel – global background correction, Insulin addition artifact is evident. 
Right panel – local background correction. At indicated time (vertical line) 
1mg/ml insulin was added. Each graph represents a single cell. 
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3.2.2. Variation of fluorophore pairs and single-tagged 4EBP1  
The conformational FRET probe design with ECFP and Citrine yielded a 
probe that was phosphorylated in the correct way but the binding to eIF4E 
was not regulated anymore. As the FRET phenomenon is not very 
predictable, there are examples of probes where simply changing the donor-
acceptor pair can make a difference between a working or a “dead” probe 
(Christiane Jost, personal communication). Therefore, I tried using the GFP2-
EYFP combination as an alternative donor-acceptor pair. GFP2 a variant of 
GFP with particularly large Stokes shift, has an excitation maximum at 399nm, 
which allows specific donor excitation without cross-excitation of the acceptor. 
It was reported to have better FRET efficiency than a CFP-YFP pair 
(Zimmermann et al., 2002). Another factor affecting FRET is that GFP and its 
derivates are weak dimers, so I also tried using the “monomeric” version of 
the fluorophores to test whether this makes a difference.  
4EBP1 was amplified by PCR and inserted into between EYFP and GFP2 to 
give a EYFP-4EBP1-GFP2 FRET probe or to a vector containing monomeric 
versions of EYFP and GFP2 to give a mEYFP-4EBP1-mGFP2 FRET probe. 
The A206K mutation abolishes the intrinsic affinity of all GFP variants to 
dimerize and have been shown to influence FRET probe performance 
(Zacharias, 2002). The resulting probes were transfected into HeLa cells and 
FRET change was measured by monitoring EYFP/GFP2 ratio. Insulin 
stimulation was not able to change the FRET ratio in either EYFP-4EBP1-
GFP2 or mEYFP-4EBP1-mGFP2 FRET probe (Figure 13). EYFP-4EBP1-
GFP2 FRET probe shows a slow non-specific decrease of the EYFP/GFP2 
ratio which could be due to a focus drift. Thus changing the fluorophore pair 
did not make the probe sensitive to phosphorylation. 
An alternative strategy to develop FRET probe would be a probe based on 
intermolecular instead of intramolecular FRET, where donor and acceptor 
fluorophores are on different proteins. Intermolecular FRET is based on a 
concept of two interacting partners, each containing one fluorophore. When 
they bind each other, this brings the fluorophores in proximity of each other 
resulting in FRET. Since 4EBP1 is a small protein, addition of two GFP 
domains, one on each end, might be too disturbing, whereas addition of only 
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one at one end might allow 4EBP1 to still function correctly. Since 4EBP1 
regulation was abolished by fusing it to two fluorophores, I went on to test 
whether it is possible to fuse it to one fluorophore and keep the regulation. 
 
 
Figure 13 Ratiometric 
FRET measurement of 
the YFP-4EBP1-GFP2 
sensor in HeLa cells 
Cells were starved of 
serum for 16 hours and 
imaged under the 
widefield microscope. 
Following excitation of 
the GFP2, GFP2 
(donor) and YFP 
(acceptor) emissions 
were captured and after 
subtraction of the 
background YFP/GFP2 
ratio was calculated. At 
indicated times (vertical 
line) 30mM Hepes 
buffer, pH7.2, 10µg/ml 
Insulin was added. 
Each color represents a 
single cell. 
 
 
 
 
 
I produced an N-terminal ECFP fusion and a C-terminal Citrine fusion of 
4EBP1 with the idea to fuse the partner for FRET to eIF4E if one of these 
constructs shows proper regulation. Figure 14 show that none of the two 
constructs is behaving as an endogenous 4EBP1 in cap pull-down, although 
the phosphorylation pattern is similar.  This result suggests that 4EBP1 
binding is sensitive to artificial modifications and does not tolerate large 
domains at either N- or C-terminus. 
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Figure 14 Regulation of ECFP-4EBP1 and 4EBP1-Citrine in MCF7 cells 
Cells were co-transfected with eIF4E and with ECFP-4EBP1 (N-terminus 
fusion) or 4EBP1-Citrine (C-terminus fusion), after 24 hours starved of serum 
for 16 hours and treated with 10 µg/ml Insulin or incubated in PBS for 30 min. 
Cell lysate or cap-beads bound fraction was analyzed by Western blot with 
total (A) and phosphospecific (B) 4EBP1 antibodies. 
 
3.2.3. A FlAsH labeling approach for making FRET probe 
 
After it became clear that 4EBP1 binding to eIF4E is altered by fusing it to 
GFP-variant fluorophores, I began looking for alternatives. A new method, 
called FlAsH labeling appeared promising as it only required a small linear 
motif and was shown to function in the cases where larger GFP derivatives 
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had interfered with biological function (Andresen et al., 2004). FlAsH is a 
fluorescent dye that becomes fluorescent only when bound to the tetracystein 
motif  on a peptide or a protein and  it is very small compared to GFP. FlAsH 
can be used as an acceptor for FRET, for example with the ECFP as a donor. 
I introduced the optimized tetracysteine motif FLNCCPGCCMEP at the N- 
and C-terminus of 4EBP1. First FlAsH-4EBP1 needed to be tested to ensure 
that its binding is physiological. In contrast to the previous attempts with 
GFP moieties, in HeLa cells after stimulation with insulin FlAsH-4EBP1 
binding to eIF4E was reduced, while PBS treatment increased the amount of 
the bound FlAsH-4EBP1 in the cap pull-down (Figure 15A). The 
phosphorylation pattern was also similar to endogenous 4EBP1 (Figure 15B). 
Finally, labeled FlAsH-4EBP1 could be directly visualized by scanning a non-
reducing gel containing protein from FlAsH labeled cells (Figure 15C). 
Encouragingly, FlAsH-4EBP1 binding to eIF4E was weaker after Insulin 
treatment than it was after PBS, as expected for the endogenous 4EBP1 
protein. In lysate a characteristic shift down after PBS was evident, indicating 
proper phosphorylation regulation. FlAsH-4EBP1 behavior was also tested in 
MCF7 cells, yielding similar results (data not shown). I continued with HeLa 
cells, since they showed greater transfection efficiency. These results suggest 
that FlAsH labeled 4EBP1 is functional and can be used for intermolecular 
FRET.  
Encouraged with successful proof that FlAsH-4EBP1 phosphorylation and 
binding was regulated in a physiological manner, I cloned the corresponding 
FRET partner – ECFP at the N- and C-terminus of eIF4E. These fusions also 
had to be tested for their ability to bind cap and 4EBP1 to ensure that eIF4E 
biological function and regulation is preserved in these constructs. HeLa cells 
were transfected with ECFP-eIF4E and eIF4E-ECFP and 
immunoprecipitations were performed. Both proteins were able to bind cap, 
although eIF4E-ECFP binds cap much more weakly than ECFP-eIF4E (Figure 
16A, left).  This could be caused by a steric hindrance, because C-terminus of 
eIF4E is close to the cap binding pocket and ECFP domain might interfere 
with the binding.   
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Figure 15 Biochemical analysis of the FlAsH-4EBP1 fusion in HeLa cells 
(A) Cells were transfected with FlAsH-4EBP1, and after 24 hours treated 
with 10µg/ml Insulin or incubated in PBS for 30 min. The cell lysate or cap-
beads bound fraction was analyzed by Western blot with 4EBP1 antibody. 
Note that almost no signal is visible for the non-transfected cells, meaning 
that endogenous 4EBP1 contributes very little to the total signal. 
(B) Same samples as in (A) detected with phosphorylation-specific 
Thr37/46 4EBP1 antibody. 
(C) Direct scan of the non-reducing gel electrophoresis. Lysate or cap-
bound fraction of FlAsH-4EBP1 transfected HeLa cells were separated on 
a gel and labeled FlAsH-4EBP1 was visualized with Bio-Rad Molecular 
Imager Pharos FX. 
 
Glutathione-sepharose beads were used to control for non-specific binding to 
the beads. To test whether eIF4E fusions could bind 4EBP1, I 
immunoprecipitated  them with an anti-GFP antibody that crossreacts with 
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ECFP, and detected whether 4EBP1 had coimmunoprecipitated (Figure 16A, 
right). Cells transfected with GFP served as a control. Both N- and C-terminal 
labeled eIF4E were able to bind 4EBP1. I then checked if ECFP-eIF4E and 
eIF4E-ECFP could bind 4EBP1 in a manner regulated by PBS and insulin. 
 
 
Figure 16 eIF4E fusions  bind cap and 4EBP1 in HeLa cells 
(A) Cells were transfected with ECFP-eIF4E (N-terminal) or eIF4E-ECFP 
(C-terminal) or empty vector, lysed and tested for the ability to bind 
cap-beads or Glutathione-beads as a control (left panel). After 
immunoprecipitation with GFP antibody, the ability to bind 4EBP1 was 
tested by detecting bound 4EBP1 (right panel). GFP also served as a 
control. 
(B) Cells were transfected with ECFP-eIF4E (N-terminal) or eIF4E-ECFP 
(C-terminal), after 24 hours starved of serum for 16 hours and treated 
with 10µg/ml insulin or incubated in PBS for 30 min. Cell lysate or anti-
GFP immunoprecipitated material was analyzed by Western blot with 
4EBP1 antibody.  
 
Figure 16B shows endogenous 4EBP1 in cell lysate, as a control that the 
treatments worked and the right panel shows the amount of 4EBP1 pulled 
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down in the anti-GFP precipitation. ECFP-eIF4E bound more 4EBP1 after 
PBS treatment, as should be the case,  but it didn’t respond to insulin, while 
eIF4E-ECFP bound more 4EBP1 after PBS and less after Insulin treatment, 
thus demonstrating normal regulation.  
These results indicated that FlAsH labeled 4EBP1 can be phosphorylated by 
mTOR and that 4EBP1 binding to eIF4E labeled with ECFP is regulated by 
mTOR phosphorylation. Therefore we proceeded to test whether changes in 
FRET can be detected upon interaction between the labeled partners. 
3.2.4. FRET measurements using FlAsH labeling 
 
For intermolecular FRET, the magnitude of FRET is directly proportional to 
the amount of binding between the interacting partners: the more molecules 
are in complex with each other, the more FRET we expect. Therefore, I 
wanted to see if under the conditions of maximal binding there is detectable 
FRET. Conveniently enough, FlAsH labeling is done in a salt solution similar 
to PBS (Hank's Buffered Salt Solution - HBSS), which means that after the 
labeling the cells are in starved of serum and we expect 4EBP1 to be bound 
to eIF4E and thus the maximal amount of FRET. I started with acceptor 
photobleaching technique, which monitors FRET by the increase of the donor 
fluorescence after the acceptor is destroyed by a strong illumination. I tested 
all 4 possible combinations of N- and C-terminal tagged 4EBP1 and eIF4E, 
trying to maximize the probability of fluorophore orientation favoring FRET. 
Cotransfection of ECFP with FlAsH-4EBP1, where we expect no interaction 
served as a negative control. FRET efficiency is calculated according to the 
following formula:  
 
FRETeff  = (Dpost-Dpre)/Dpost, for all Dpost > Dpre 
 
where Dpre is the donor fluorescence before the bleaching and Dpost is the 
donor fluorescence after the bleaching . 
In general, acceptor photobleaching on live cells was quite variable and poorly 
reproducible. Figure 17 shows an example of an acceptor photobleaching 
experiment using ECFP-eIF4E and 4EBP1-FlAsH. A cell containing ROI_1 
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(Region Of Interest) is bleached, and FRET efficiency is calculated from the 
donor (ECFP-eIF4E) channel. A cell containing ROI_2 is not bleached and 
serves as a control to estimate noise of the live imaging. FRET efficiency in 
this example is 0 for both bleached and unbleached cells. From the signal in 
ROI_2 it is clear that the post bleaching images for both donor and acceptor 
are weaker also in the non-bleached area, for an unknown reason. In other 
cases the same donor-acceptor combination showed apparent FRET 
efficiency of up to 7%. However, FRET efficiency for cells where acceptor was 
not bleached was similar or even greater than in the cell where acceptor was 
bleached (up to 10%). Moreover, negative control samples, containing ECFP 
and 4EBP1-FlAsH also showed up to 3% FRET efficiency, which was clearly 
an artifact of measurement, since we expect no interaction between these 
proteins. We concluded that this technique has too much variability and too 
low signal/noise ratio to be useful. Table 3.1 summarizes the data from all 
acceptor photobleaching experiments. N-terminal FlAsH-4EBP1 did not show 
any FRET with either eIF4E construct, while C-terminal 4EBP1-FlAsH 
presented values that varied between 0 and 7% FRET efficiency. Notably, 
non bleached cells displayed FRET efficiency in a similar range. 
 
Table 3.1 FRET efficiency, measured by acceptor photobleaching 
Donor Acceptor 
Number of 
cells 
measured 
FRET 
efficiency, 
% 
FRET efficiency, 
%, non 
bleached  cells 
ECFP-eIF4E 
FlAsH-
4EBP1 
3 all 0 ND 
ECFP-eIF4E 
4EBP1-
FlAsH 
4 0, 1, 1, 7 0, 0.4, 7,10 
eIF4E-ECFP 
FlAsH-
4EBP1 
3 all 0 ND 
eIF4E-ECFP 
4EBP1-
FlAsH 
3 4, 4, 5 0, 1.6, 1.5 
ECFP 
4EBP1-
FlAsH 
2 0, 3 ND 
FRET efficiency is shown for individual cells, ND – Not Determined. 
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Figure 17 FRET measurement by Acceptor photobleaching 
(A) Cells were cotransfected with ECFP-eIF4E and 4EBP1-FlAsH, labeled 
with FlAsH after 36 hours and imaged using confocal microscopy. Pre 
and post bleaching images are shown for  donor (ECFP-eIF4E) and 
acceptor (4EBP1-FlAsH) channels. FRET efficiency was calculated for 
in indicated Regions Of Interest (ROI) inside the bleached region (ROI 
1) and outside (ROI 2). 
(B) Quantification of the ROIs shown in (A). Fluorescence values for 
Donor (D) and Acceptor (A) channels are displayed pre and post 
bleaching as well as FRET efficiency calculated from these values. 
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A factor leading to the low FRET efficiency, observed by acceptor 
photobleaching experiments could be a difference in fluorophore strength 
between ECFP and FlAsH. ECFP is much brighter than FlAsH and it is 
possible that even if the FRET efficiency is high for the FlAsH, the increase in 
the ECFP donor fluorescence after bleaching is small and is hard to detect. I 
therefore tried to estimate FRET using sensitized emission method, which 
calculates FRET based on the acceptor fluorescence after donor excitation. 
Sensitized emission is conceptually straightforward but technically challenging 
method for FRET measurement. The challenge is that when detecting 
sensitized emission from the acceptor upon donor excitation one must correct 
for a number of factors, mainly for the donor emission overlapping with the 
acceptor emission (bleed-through) and the direct excitation of the acceptor 
when exciting the donor. These corrections can be made using samples 
containing only donor and only acceptor fluorophores. One must assume that 
these correction factors are invariable within the image and between different 
cells and this is of course an approximation, so one must take the values with 
a grain of salt and test them by relevant biological assays. 
Table 3.2 summarizes the results for the sensitized emission FRET 
measurements. 3 out of 4 combinations showed FRET with the ECFP-eIF4E  
 
Table 3.2 FRET efficiency, measured by sensitized emission 
Donor Acceptor 
Number of 
cells 
measured 
FRET efficiency, % 
ECFP-eIF4E FlAsH-4EBP1 11 3,7,14,5,6,12,14,16,14,21,24 
ECFP-eIF4E 4EBP1-FlAsH 5 0,0,2,5,7 
    
eIF4E-ECFP FlAsH-4EBP1 6 all 0 
eIF4E-ECFP 4EBP1-FlAsH 5 1,3,4,4,5 
    
ECFP 4EBP1-FlAsH 5 0,0,15,15,17 
FRET efficiency is shown for individual cells. 
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FlAsH-4EBP1 combination showing highest values (on average 12%). 
Unfortunately the negative control also showed up to 17% FRET, 
demonstrating that biological variability causes noise in the similar range of 
the FRET measured in experiments. 
As a biological test, I decided to perform stimulation with Insulin and inhibition 
of Rapamycin to see if these can change the FRET efficiency, as observed 
through sensitized emission. If the calculated FRET values are indeed 
reflecting the interaction between labeled 4EBP1 and eIF4E, than we expect a 
change upon Insulin stimulation and Rapamycin inhibition of TOR. I used 
ECFP-eIF4E and FlAsH-4EBP1 combination, which appeared most 
promising, often showing relatively high calculated FRET. Unfortunately, as 
shown in Figure 18 neither insulin nor Rapamycin were able to change FRET 
significantly, suggesting that the calculated FRET is not biologically relevant. 
The graph of FRET efficiency against time is a good example to how noisy 
this method is in live cells. From one point to the next calculated FRET 
efficiency can change 2-fold, probably due to rearrangement of fluorophores 
in the cells, cells movements and focus changes associated with it. Figure 19 
shows the same kind of experiment on a negative control sample (ECFP and 
FlAsH-4EBP1). One of the two cells showed no response to either insulin or 
Rapamycin, while another cell displayed an artifact of addition after both 
treatments.  
In conclusion sensitized emission data did not confirm that the intermolecular 
FRET occurs, as calculated FRET was not responsive to physiological 
stimulation or inhibition that biochemically was shown to affect the interaction 
between the labeled proteins. 
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Figure 18 FRET measurement by Sensitized Emission 
Cells were cotransfected with ECFP-eIF4E (N-terminal) and FlAsH-4EBP1 (N-
terminal), after 36 hours labeled with FlAsH and imaged using confocal 
microscopy. (A) Images are shown for donor (ECFP-eIF4E), acceptor 
(4EBP1-FlAsH), sensitized emission – acceptor emission (donor excitation) 
and calculated FRET. FRET efficiency was calculated in indicated Regions Of 
Interest (ROI) and plotted in (B). At indicated times (vertical line) 10 µg/ml 
Insulin or 20µM Rapamycin was added. Labels indicate emission channel, 
upon excitation in parenthesis. 
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Figure 19 FRET measurement by Sensitized Emission – Negative control 
Cells were cotransfected with ECFP and FlAsH-4EBP1 (N-terminal), labeled 
with FlAsH after 36 hours and imaged using confocal microscopy. (A) Images 
are shown for donor (ECFP), acceptor (4EBP1-FlAsH), with sensitized 
emission – acceptor emission (donor exitation) and calculated FRET. FRET 
efficiency was calculated in indicated Regions Of Interest (ROI) and plotted in 
(B). At indicated times (vertical line) 10 µg/ml Insulin or 20µM Rapamycin was 
added. Labels indicate emission channel, upon excitation in parenthesis. 
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Finally, I tested the intermolecular FRET approach by chemically bleaching 
FlAsH. This type of FRET measurement has a similar principle to acceptor 
photobleaching but the bleaching is chemical, using BAL (British-Anti-
Lewisite, 2,3-dimercapto-1-propanol) – a chemical with a higher affinity for 
arsenicals than EDT or FlAsH. It strips FlAsH off the tetracysteine motif very 
effectively and thus destroys the acceptor. This should lead to an increase of 
the donor (ECFP) fluorescence if there is any FRET (Adams et al., 2002). 
Addition of 5mM BAL leads to the rapid drop in FlAsH fluorescence and 
simultaneous increase the ECFP for a well-characterized KCP-F probe (Jost 
et al., 2008)(Figure 20).  
Negative control (ECFP and FlAsH-4EBP1) did not exhibit an increase in 
donor channel upon BAL addition, while positive control KCP-F did as 
expected (Figure 21A). Disappointingly, all the combinations of FlAsH 
labeled 4EBP1 and ECFP labeled eIF4E displayed no elevation in donor 
channel after BAL, indicating that no FRET takes place between these 
fluorophores (Figure 21B). This is surprising given the small size of the 
proteins and the fact that both proteins have been labeled on each end and 
all combinations tested. One possible explanation could be that dipoles of 
the fluorophores are arranged at an angle that does not allow FRET. 
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Figure 20 FRET test by destroying FlAsH with BAL – KCP-F 
Cells were transfected with KCP-F, after 36 hours labeled with FlAsH and 
imaged using confocal microscopy. (A) Pseudocolored images are shown for 
donor (ECFP) and acceptor (FlAsH) before and after addition of BAL. Note 
that donor fluorescence is completely destroyed by BAL. (B) Normalized 
fluorescence of donor and acceptor plotted against time. FlAsH is 
disappearing in less than a minute with a corresponding increase in ECFP 
signal. 
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Figure 21 4EBP1 fusions to FlAsH  do not show FRET  
Cells were cotransfected with indicated combinations of 4EBP1 fused to 
FlAsH and eIF4E fused to ECFP or ECFP alone, after 36 hours labeled with 
FlAsH and imaged using confocal microscopy. (A) Positive control KCP-F 
shows an increase is donor fluorescence after addition of BAL while negative 
control (ECFP alone with FlAsH-4EBP1) doesn’t. (B) None of the 
combinations of 4EBP1 fused to FlAsH and eIF4E fused to ECFP shows 
FRET. 
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3.3. Discussion 
3.3.1. 4EBP1 regulation is disturbed by fusion to GFP  
 
Development of the FRET probe for TOR signaling proved to be challenging. 
The conventional strategy of a conformational probe based on GFP variants 
as a FRET pair did not work, because inserting 4EBP1 in between ECFP and 
Citrine abolished regulation of binding to eIF4E. The ECFP-4EBP1-Citrine 
fusion was still recognized by TOR kinase and phosphorylated properly. At 
least a fraction of FRET probe was able bind to eIF4E, as shown by cap 
pulldowns, but this fraction does not respond to phosphorylation by TOR. This 
is most probably because addition of two globular GFP domains changes the 
ability of 4EBP1 to bind eIF4E. An alternative explanation would be that 
because of overexpression, TOR cannot phosphorylate all available FRET 
probe molecules and there is always an unphosphorylated fraction that binds. 
This is not likely to be the case, because than we would still expect the 
increase in binding after inhibition of TOR (starvaton with PBS or rapamycin), 
which is not occurring (Figure 9A, last lane). Of course one would have to 
ensure that there is enough eIF4E to bind in the cell, which was achieved by 
cotransfection of eIF4E together with FRET probe. 
Given a small size of 4EBP1 (12 KDa) it is easy to imagine that addition of 
two 25 KDa GFP domains can change its behavior. As turned out in 
subsequent experiments one GFP domain was still too much, irrespective of 
which end of the protein it was attached to. 4EBP1 tagged with one GFP-
variant at either end of the protein was also binding constitutively and not 
regulated by TOR activation or inhibition. Since 4EBP1 is unstructured in 
solution, it is conceivable that it needs its dynamic conformation to make 
proper contacts with eIF4E and a bulky GFP domain restricts its 
conformational freedom and thus affects binding properties to eIF4E.  
Surprisingly, phosphorylation of all tested FRET probes was similar to the 
endogenous 4EBP1, indicating that it can be recognized by TORC1. For 
TORC1, raptor was proposed to act as an adaptor protein, recognizing the 
TOS motif and thus bringing TORC1 substrates to the TOR kinase. In 4EBP1, 
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the TOS motif is at the very C-terminus, but apparently it can still function in 
the FRET probe fusion with GFP domain fused directly after it. 
Many FRET probes for kinases utilize a strategy where a short peptide 
sequence (either a generic consensus or a known substrate) is sandwiched 
between a FRET pair and phosphorylation of the peptide triggers a 
conformational change, leading to a change in FRET (Schleifenbaum et al., 
2004). Sometimes to create a larger conformational change, a 
phosphotyrosine or phosphoserine binding domain is included to recognize 
and bind phosphorylated substrate (Kurokawa et al., 2001) (Sasaki et al., 
2003; Zhang et al., 2001). When we considered possible FRET probe designs 
we decided to use full-length 4EBP1 to preserve all its regulatory sequences 
for the best specificity.  
Phosphorylation alone of the FRET sensor was not enough to see a change 
in FRET. This is consistent with the idea that conformational change in 4EBP1 
is induced by binding to eIF4E and free 4EBP1 in solution has no stable 
structure. This was the case in HEK293 and HeLa cells in transient 
transfection and also in stable line of HEK 293 cells selected for low levels of 
FRET probe expression. The idea behind selecting low-expressing cell line 
stemmed from observation that sometimes there was weak response to 
insulin in dim cells and selecting cells with low expression would increase the 
fraction of probe that was responding to stimulation. Later it turned out that it 
was an effect of Insulin addition (changing background fluorescence), which 
was more evident in cells with low signal. This example highlights the 
importance of proper controls and caveats in interpreting FRET probes 
results. 
Alternative FRET pair of GFP2 as a donor and YFP as an acceptor, did not 
produce FRET change either, which strengthens the conclusion that it is the 
presence of the GFP domain that affects the binding and using an another 
FRET pair cannot solve this issue. Using “monomeric” mutants of GFP did not 
make a difference in this case, suggesting that a tendency to dimerize does 
not play a role in this FRET probe, probably because its primary problem is 
inability to undergo binding in a regulated manner.  
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3.3.2. FlAsH labeled 4EBP1 is functional but produces no 
FRET  
 
Tetracystein motif of 12 amino acids used for FlAsH labeling did not interfere 
with binding, supporting that it was indeed a steric problem in the GFP fusions 
that affected binding. This was a very encouraging development allowing to 
explore the possibility to make an intermolecular FRET probe. Unfortunately, 
despite having properly regulated binding to eIF4E, FlAsH labeled 4EBP1 did 
not show FRET response. This was tested by a number of different 
approaches such as: acceptor photobleaching, sensitized emission and 
chemical bleaching of the acceptor.  
Acceptor photobleaching and sensitized emission data were not conclusive, 
because they were badly reproducible and signal to noise ratio was low. In 
live cell imaging there are many factors that influence the signal; if the signal 
is not strong enough to overcome fluctuations from the biological variance and 
measurement and analysis imprecision, the usefulness of the approach is 
limited. This was the case for acceptor photobleaching, where calculated 
FRET efficiency was varying from cell to cell and was comparable to the 
negative control samples. For most of the combinations of N- and C-terminally 
labeled 4EBP1 and eIF4E FRET efficiency was zero or low (not exceeding 
7%), suggesting that if there is FRET happening, it is not very efficient and 
would be hard to detect reliably.  
I then focused my attention on sensitized emission method, thus 
concentrating on the acceptor (FlAsH). It was possible that because FlAsH 
had weaker fluorescent signal than ECFP, more of FlAsH would participate in 
FRET and detecting sensitized emission could be a better way to assess 
FRET. Indeed, one of the combinations (ECFP-eIF4E and FlAsH-4EBP1) did 
show more apparent FRET than others, but it was not responsive to 
stimulation with insulin. In addition signal/noise ratio was low and negative 
control samples gave similar FRET values. Sensitized emission method uses 
correction factors for calculating FRET, which are prone to introduce 
mistakes. The factors are calculated from control cells with specific 
parameters of brightness, expression levels and stoichiometry of fluorophores 
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and then are applied to the cells that may have slightly different parameters.  
Also such factors as donor and acceptor brightness and stoichiometry are 
influencing FRET detection. Ideal donor/acceptor stoichiometry is 1:1 and 
FRET can still be detected for the ratios varying from 0.1 till 10 (Chen et al., 
2006). In reality, there is no way to know the stoichiometry in the cell for 
intermolecular FRET, as protein concentrations will depend on multiple 
parameters, such as expression efficiency, stability and degradation 
dynamics.  
Acceptor chemical bleaching with BAL proved unambiguously that there is no 
FRET happening between differently labeled 4EBP1 and eIF4E. Chemical 
bleaching strips FlAsH completely off the protein, making it non-fluorescent. 
This happens very fast, and it is a better method than photobleaching, 
because there is no danger of bleaching the donor. All combinations looked 
like the negative control, namely there was no increase in the donor channel, 
after destroying the acceptor fluorescence. It is surprising that none of the 
combination of N- and C-terminaly labeled 4EBP1 and eIF4E produced any 
measurable FRET. Given the small size of 4EBP1 and also eIF4E and 
analysing at the structure of eIF4E with 4EBP1 peptide bound (see Figure 22) 
it is plausible that there would be some FRET between the two. Although we 
cannot predict the location of full-length 4EBP1 N and C termini, eIF4E N-
terminus is facing the side where 4EBP1 binds and it is quite flexible, because 
it is not visible in the structure (Tomoo et al., 2005). Based on the structure 
only the central part of 4EBP1 containing the eIF4E binding motif becomes 
structured upon binding, leaving a lot of flexibility to the fluorophore fused to 
either N or C terminus. Still despite biochemical proof of binding between the 
two partners there is no FRET occurring based on the chemical bleaching 
experiment.  
The absence of FRET could be attributed to the unfavorable orientation of 
dipoles of the FRET pair, which is an unpredictable parameter. In addition, 
non-stoichiometric ratio between the fluorophores with excess of non-
interacting fluorophores can mask FRET. 
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Figure 22 Structure of eIF4E 
with 4EBP1 peptide and cap 
analog 
Structure of the ternary 
complex of m7GpppA – eIF4E 
– 4E-BP1 peptide. eIF4E is 
shown in green, 4EBP1 peptide 
in red. Some residues 
important for interactions and 
m7GpppA cap analog are 
shown as ball and stick model. 
Modified from (Tomoo et al., 
2005) 
 
 
 
 
 
4EBP1 was reported to be regulated by ubiquitination that leads to its 
degradation (Elia et al., 2008), which could contribute to the difference in 
concentration of interacting proteins. Lastly, the sensitivity or dynamic range 
of FRET probes is usually not large and extensive optimization of linker 
sequences may be necessary to obtain a good signal. One striking example is 
a recent paper from fresh Nobel laureate Roger Tsien laboratory (Hires et al., 
2008). While developing a FRET sensor for glutamate, the sensitivity of the 
original FRET construct was only around 7% change in the donor/acceptor 
ratio. After having screened through 176 truncation combinations by varying 
the length of linking regions between the glutamate binding domain and donor 
and acceptor, they found 1! combination with significantly increased 
sensitivity. Moreover, there was no rational explanation that could explain why 
this combination was so much better than others. This example demonstrates 
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how challenging the development of FRET probes can be and how 
unpredictable the process is. 
It is impossible to exclude that FRET occurs in the probes that I have tried, it 
could as well be undetectable using the methods employed. All the results 
taken together for intermolecular FlAsH-based probe, suggest that even if 
FRET occurs, its magnitude is not big enough to make it a useful tool to 
monitor TOR activity. One possible direction for the future could be using 
FLIM to detect FRET, as this method has some advantages (see introduction) 
over intensity-based methods. 
In conclusion, both intramolecular and intermolecular FRET probes were 
designed and tested using different FRET pairs and a number of cell lines. 
Several different constructs and a range of methods were utilized to assess 
FRET efficiency using FlAsH labeling but no acceptable probe was identified. 
Future studies using different strategies are needed to achieve the goal of 
developing a sensor for TOR activity in vivo. 
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4. Analysis of MAP4K3 function in Drosophila 
melanogaster 
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4.1. Introduction - amino acid signaling and fat 
metabolism 
4.1.1. Nutrient signaling by TORC1 
 
TOR kinase regulation by nutrients, specifically amino acids, is the most 
conserved functions of TOR, yet it is quite poorly understood. Amino acids 
withdrawal results in decreased TORC1 activity towards its substrates, S6K 
and 4EBP but the elements mediating this input remain largely unknown 
(Avruch et al., 2006). Of note is that insulin is able to induce activation of PI3K 
and AKT but not TORC1 in amino acid deprived cells. This indicates that 
there are two independent pathways converging on TORC1, with amino acid 
branch being dominant one, that is, it can block insulin induced TORC1 
activation, and is necessary for insulin stimulation to be successful (Hara et 
al., 1998).  This makes perfect sense in terms of cell physiology – growth 
promoting signals can only be executed, when there are enough building 
blocks to support growth.  
A number of proteins have been reported to be involved in amino acids 
signaling to TORC1 but their interrelationship is not clear and they do not 
constitute a signal cascade, that could explain the signal flow from amino 
acids to TORC1 (as is the case for Insulin cascade). For example, a homolog 
of yeast Vps34 (vacuolar protein sorting 34), Type III PI3-kinase that produces 
PI(3)P was shown to participate in amino acid regulation of TORC1. 
Overexpression of hVps34 or the associated hVps15 kinase activates S6K1, 
and insulin stimulation of S6K1 is blocked by microinjection of inhibitory anti-
hVps34 antibodies, overexpression of a FYVE domain construct that 
sequesters the hVps34 product PI(3)P, or small interfering RNA-mediated 
knock-down of hVps34 (Byfield et al., 2005; Nobukuni et al., 2005). This 
regulation is confusing, given that Vps34 is required for starvation-induced 
autophagy (Mizushima et al., 2002), while TORC1 is a negative regulator of 
autophagy (Lum et al., 2005). 
Amino acids have been shown to act on TORC1 independently of TSC 
complex but they regulate Rheb binding to TOR, in a manner that is not 
completely understood (Long et al., 2005b). Overexpression of Rheb can 
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overcome amino acids starvation-induced TORC1 inhibition, supposedly by 
flooding the cell with very high concentrations of Rheb-GTP, that is able to 
activate TORC1 (Avruch et al., 2006). 
Recently small GTPases called Rags were reported to mediate amino acids 
activation of TORC1 (Kim et al., 2008; Sancak et al., 2008). Rags function as 
heterodimers and interact with TORC1. Inactive GDP-bound Rag mutants can 
block amino acid activation of TORC1, while constitutively active GTP-bound 
mutants make TORC1 insensitive to amino acids deprivation. Sancak at al 
propose that Rags act, similarly to amino acids, by promoting translocation of 
TORC1 from distributed cytoplasmic puncta to the perinuclear compartment 
containing its activator Rheb. Genetic studies in Drosophila demonstrated that 
Rag GTPases regulate cell growth, autophagy and viability during starvation 
(Kim et al., 2008).  
Additional component recently discovered to play a role in amino acid 
signaling to TORC1 is a Drosophila gene CG7097, an ortholog of mammalian  
MAP4K3 (Findlay et al., 2007). It was discovered in an RNAi screen in 
Drosophila S2 cells looking for new kinases affecting phosphorylation of S6K 
in the sensitized background of TSC1 depletion. MAP4K3 was needed for 
phosphorylation of S6K induced by amino acids, MAP4K3 kinase activity was 
stimulated by amino acids but not insulin and overexpression of MAP4K3 
promoted rapamycin-sensitive phosphorylation of S6K and 4EBP. In addition, 
knockdown of MAP4K3 levels caused a decrease in cell size, phenocopying 
Rapamycin treatment or Rheb knockdown. Taken together these results 
provide evidence that MAP4K3 plays a role in transducing nutrients 
availability signal to TORC1, but how it does so or its relationship to other 
components of nutrients-TORC1 pathway remains to be established.  
We decided to use Drosophila model to investigate the function of MAP4K3 
as a nutrient sensor on the organism level. Cell culture is a very convenient 
and widely used experimental system but it does not allow analysis of gene 
function in the context of intact organism. Artificial culturing conditions and 
absence of high level systemic regulation (e.g. hormonal) necessitate 
complementary studies in the whole organism. One recent example, 
highlighting importance of verification of cell culture studies in the model 
organism is Vps34 case. While Vsp34 was reported crucial for amino acids  
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regulation of TORC1 in cultured cells (Byfield et al., 2005; Nobukuni et al., 
2005), Drosophila animals lacking Vps34 gene product have normal TOR 
activity and Vps34 doesn’t seem to activate TOR in this system (Juhasz et al., 
2008). This could either reflect differences between Drosophila and 
mammalian Vps34 functions or the results in cell culture do not reflect the 
physiological function of the protein in the organism.  
Apart from the newly proposed function as an activator of TOR in response to 
amino acids, MAP4K3 has been poorly characterized and the literature about 
it is quite scarce. Mammalian MAP4K3 is also known as Germinal-center Like 
Kinase (GLK), it belongs to the GCK (Germinal Center Kinase) family 
(Kyriakis, 1999). Drosophila MAP4K3 is a large kinase of 1218 amino acids 
(947 for a smaller isoform B) with two defined domains: Ser/Thr kinase 
domain and a Citron homology domain (Figure 23). Citron homology domain 
is annotated as a small GTPase regulatory domain, pointing at small 
GTPases as possible interaction partners.  
 
 
 
Figure 23 Domain structure of MAP4K3  
Isoform A of MAP4K3 was annotated for known domains using SMART tool 
(Schultz et al., 1998). 
 
Human MAP4K3 was identified as an interacting partner for endophilin 1, a 
protein involved in clatrin-mediated endocytosis. MAP4K3 can bind SH3 
domain of endophilin 1 and is needed for activation of c-Jun N-terminal 
Kinase (JNK) by endophilin 1 (Ramjaun et al., 2001). JNK is one of the four 
main branches of the MAP (Mitogen Activated Protein kinase) pathway, along 
with ERK, p38 and ERK5. Interestingly, MAP kinase signaling, a vast 
signaling network regulating response to mitogens and stress, has been 
recently linked to TOR signaling. Several reports demonstrated crosstalk 
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between MAP kinase signaling and insulin/TOR signaling  (Herbert et al., 
2002; Ma et al., 2005; Roux et al., 2004). The later two of these show that 
TSC2 is the point where ERK (extracellular signal-regulated kinase) signaling 
is feeding into TOR pathway, modulating TOR activity, while Hebert et al 
show that 4EBP phosphorylation induced by ERK is TOR dependent.  
Another study implicates p38 and ERK branches of MAPK pathway in amino 
acid signaling to S6K, surprisingly, in a seemingly TOR-independent way 
(Casas-Terradellas et al., 2008). This study shows that ERK and p38 are 
activated by amino acids and signal to their effector kinases called RSK (p90 
ribosomal S6 kinases) and MSK (mitogen- and stress-activated kinases) in 
addition to activating S6K1 by phosphorylation on Thr421/Ser424. 
Moreover, a component of TORC1, raptor, turns out to be a target of RSK 
kinase, effectively making TORC1 an effector of ERK signaling (Carriere et 
al., 2008). RSK is a family of four kinases in mammals, they can 
phosphorylate raptor in vitro and in vivo on 3 closely spaced Ser residues at 
the conserved region. Phosphorylated raptor is then able to significantly 
increase TORC1 kinase activity towards 4EBP1 and S6K1, presumably 
through promoting a catalytically more active conformation of TORC1. 
Thus it appears that TOR and MAPK pathways have more in common than 
previously appreciated. ERK and p38 signaling feed into TORC1 signaling 
both up- (TSC2) and downstream (S6K) of TORC1 as well as affecting it 
directly (raptor). This co-ordination of two central pathways controlling growth 
and proliferation has a clear rational from cell point of view. How amino acids 
feed into this regulatory circuitry remains to be established. MAP4K3 as a 
kinase regulated by amino acids and affecting TORC1 and at the same time 
belonging to the family of MAP kinases may play an interesting role. We 
approached its function using genetic approach in Drosophila. 
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4.2. Results 
4.2.1. Identification of the Drosophila MAP4K3 mutant 
 
To analyze gene function in Drosophila many mutagenesis screens have 
been performed. One of the most popular methods is transposon 
mutagenesis, where a mobile genetic element is mobilized and randomly 
inserted in a genome (Adams and Sekelsky, 2002). If inserted into a gene or 
its regulatory region, an insertion can result in partial or complete mutation of 
a given gene. Many fly strain carrying specific insertions are available from 
various large-scale mutagenesis screens through fly stocks repository 
centers, such as Bloomington stock center (http://flystocks.bio.indiana.edu).  
I characterized several insertions in the Drosophila ortholog of MAP4K3, 
which is a gene called CG7097 to see if any of them affects expression of the 
gene. Figure 24A shows the structure of a gene and its products as well as 
sites of transgenes insertions that I have tested. MAP4K3 is a large gene, 
spanning almost 50 Kb. It has 2 alternatively spliced isoforms that differ in the 
exon9 (isoform CG7097-RA has an alternative 5’ splice site, which makes it 
some 800 bp longer than CG7097-RB). 3 stocks that have insertions in 
CG7097 were tested: P(EP)2445 which is a promoter insertion and two 
insertions in the intron2 – PBac(WH)CG7097(f04135) and 
P(lacW)l(2)SH1261. Compared to wild-type flies (strain w1118) 
P(lacW)l(2)SH1261 had almost no mRNA left (around 1%), while two other 
insertions had less dramatic decreases of mRNA level (Figure 24B). I 
concluded that P(lacW)l(2)SH1261 is a strong hypomorphic mutant of 
MAP4K3 (further named MAP4K3).  
To investigate expression pattern of MAP4K3, quantitative PCR analysis was 
done on samples from different developmental stages and tissues of 
wandering 3rd instar larvae (Figure 24C). MAP4K3 is ubiquitously expressed 
throughout development with maximal expression levels in pupal stages and 
adult males. It is expressed in both proliferating (imaginal wing disc) and 
endoreplicative (fat body, body wall, salivary gland) larval tissues. 
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Figure 24 Genomic structure of MAP4K3, its expression in transgenic 
lines  and developmental stages and tissues. 
(A)CG7097 gene is shown in blue, mRNA transcripts in black, exons as 
boxes, introns as lines, coding sequence (CDS) is in yellow. Transposone 
insertion sites are indicated by blue triangles below. Three insertions 
underlined by a red line were ordered and analysed. Black scale at the top is 
a location on 2R chromosome arm. (B) MAP4K3 expression in transgenic 
lines indicated in (A). Note that l(2)SH1261 is a strong mutant. (C) MAP4K3 
expression during development and in different tissues of OreR strain. L1 - 1st 
instar, L2 – 2nd instar, wL3 – wandering 3rd instar. 
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Interestingly, fat body had one of the highest levels of expression, suggesting 
a possible role in fat metabolism. Having confirmed that l(2)SH1261 is a 
mutant I went on to see what effects this mutation causes on the organism 
level. 
 
4.2.2. Phenotypic characterization of MAP4K3 mutant 
 
To study flies mutant for MAP4K3, I obtained flies harboring the l(2)SH1261 
insertion, which was produced in a screen for lethal mutations on the 2nd 
chromosome (Oh et al., 2003). I initially assumed it to be lethal. Surprisingly, it 
turned out that it is homozygous viable and probably initial lethality phenotype 
was assigned because under crowded conditions very few homozygous 
animals survive. Under controlled growth conditions (50 animals/vial) most of 
the MAP4K3 mutant animals survived to adulthood, but appeared weak and 
many died upon hatching by getting stuck in the food (Figure 25A). There was 
also some pupal lethality, indicating that developmental program was 
compromised or perhaps the metabolic stores were not sufficient. Mutant 
MAP4K3 flies were fertile and produced viable progeny.  
MAP4K3 has been shown to affect TORC1 activity in drosophila and 
mammalian cells (Findlay et al., 2007). Several mutants in the have been 
described in Drosophila affecting TOR pathway. Their phenotypes include 
lethality (dTOR itself, (Zhang et al., 2000) and rheb (Saucedo et al., 2003)), 
growth and metabolism (chico (Bohni et al., 1999), S6K (Montagne et al., 
1999)) and , stress sensitivity (d4EBP (Teleman et al., 2005a)).  Therefore, 
we tested MAP4K3 mutants for growth, metabolism and stress resistance. 
As MAP4K3 is important for sensing amino acids in cells, we tested how 
MAP4K3 mutants survive under different starvation conditions. When starved 
(agarose with PBS) MAP4K3 mutants died faster than wild-type (wt) animals 
(Figure 25B). When reared on starvation medium supplemented with 
carbohydrates (1% Sucrose) or with amino acids (all 20 amino acids, at the 
concentrations equal to those in Drosophila Serum Free Medim –  SFM) 
MAP4K3 mutants also died faster than wt flies(Figure 25C,D). Increased 
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starvation sensitivity could stem from lower energy stores or from increase 
energy expenditure (see below). 
 
 
 
Figure 25 Survival of the MAP4K3 mutants under different conditions 
(A) 50 first instar larvae (L1) were seeded into normal food and counted after 
reaching pupal stage, upon hatching and 2 days after hatching. (B-D) 20-30 
first instar larvae were seeded into medium containing PBS (B), 
PBS+1%Sucrose (C) or PBS+Amino acids (D). Number of alive flies was 
monitored at the indicated time points. All experiments were done in 
triplicates. * indicates p<0.01. 
 
TOR is known to regulate cell and organ size (Oldham et al., 2000) and 
MAP4K3 was shown to be able to regulate size in cells (Findlay et al., 2007). I 
tested if MAP4K3 can regulate size in vivo. Drosophila wing is a very sensitive 
and well-defined system for size measurements. MAP4K3 mutants displayed 
a reduction in wing area, indicating that MAP4K3 is required for attaining 
normal organ size (Figure 26A). Final organ size is determined by the number 
of cells and the size of each cell. Wing cells of MAP4K3 mutant are smaller 
(Figure 26B), suggesting that it is the size of individual cells that results in the 
smaller wing. Weight measurement also hinted that MAP4K3 mutants are a 
bit smaller then wt, but these measurements are tricky to do and many flies 
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are needed, so the difference did not reach statistic significance.  Thus 
MAP4K3 can regulate cell and organ size in Drosophila. 
 
Figure 26 MAP4K3 regulates organ and cell size 
(A) Wing area was measured using ImageJ software for wt and mutant male 
flies, grown under controlled conditions. p=4.5*10-8 , n=5. (B) Cells hairs in the 
constant area in the posterior of the wing were counted and average cell size 
calculated by dividing the area by the number of cells. p=3.1*10-5 , n=5. 
 
Apart from being weak, MAP4K3 mutants develop slower than their wt 
counterparts. They grow slower and it takes them longer to reach pupation 
stage and to hatch (Figure 27A). There is quite a lot of variability in the 
population as evident from different sizes of mutant larvae in Figure 27C and 
also from the lower slope of the pupation curve (Figure 27A). While most wt 
animals pupate on the same day, MAP4K3 pupation spreads over a few days, 
reflecting heterogeneity in the population. Some animals are indistinguishable 
from wt while others are severely delayed. This suggests that there are other 
modulatory factors that in the absence of MAP4K3 modify growth rate. 
Interestingly, when grown on diluted (20% of normal food) MAP4K3 mutants 
develop at the same rate as the wt (Figure 27B). This may be surprising at the 
first sight, but it actually makes sense considering the role of MAP4K3 as a 
sensor for nutrients (amino acids). If we assume MAP4K3 functions to sense 
amino acids and fully activate growth, when growth is slowed down under low 
nutritional conditions, MAP4K3 is not active. Therefore under low nutritional 
conditions MAP4K3 function does not manifest itself and there is no difference 
between wt and mutant animals growth rate. 
Metabolism is among the processes regulated by TOR (Britton et al., 2002). 
MAP4K3 mutant flies displayed reduced fat levels, as measured by the 
 76 
amount of triglycerides, which are the main form of fat storage in Drosophila 
(Van der Horst, 2003). 
 
Figure 27 MAP4K3 mutant have a delay in growth 
Representative pupation curve of MAP4K3 mutant compared to w1118 grown 
at controlled density on normal food (A) or 20% of normal food (B). (C) 
Examples of growth delay in 3rd instar larvae of MAP4K3 mutant (3 larvae on 
the right) vs. w1118 (3 larvae on the left) at 4 (bottom) and 5 (top) days after 
egg laying (AEL). Note the variability in size of MAP4K3 mutants. 
 
This effect was most pronounced in adult flies (~40% reduction in 3 days old 
flies, up to 70 % reduction in 5 days old flies) but also detectable in wandering 
3rd instar larvae, although smaller in magnitude (Figure 28A,B). To make sure 
that the phenotype is caused by mutation of the MAP4K3 gene, we generated 
a precise excision of the P-element  from the gene. Flies carrying l(2)SH1261 
insertion were crossed to the strain carrying a trasposase and in the next 
generation the progeny was screened for the absence of the marker gene 
(w+) that is encoded by the insertion construct.  
Excision of the transposon is not always a precise process, sometimes parts 
of the neighboring genomic sequence can be deleted as well. We verified the 
precision of the excision by PCR performed on the insertion site as shown in 
Figure 29A. 
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Figure 28 Fat levels are reduced in MAP4K3 mutants  
Adult male flies (A,C,D) or wandering 3rd instar female larvae (B) grown under 
controlled conditions were homogenized and triglycerides levels measured 
and normalized to protein. (C) Precise excision of the P-element insertion in 
MAP4K3 gene rescues fat phenotype. (D) Driving Rheb ubiquitously rescues 
the fat at least partially. Driving Rheb in wt background does not increase fat. 
(E) Further reducing MAP4K3 levels by using deficiency allele 
Df(2R)Exel6069, does not decrease fat levels.  
 
Out of four excision lines, two (lines 4 and 5) turned out to be precise and two 
imprecise (Figure 29B).  
The fat phenotype is rescued by a precise excision but not completely (Fgure 
28C). It might be that the w1118 flies are fatter than the background in which 
P-element insertion was made. Another possibility is that the excision is not 
really precise, removing or leaving behind small number of nucleotides, which 
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one wouldn’t see by running the PCR product on a gel, but would still affect 
the gene.  
 
 
Figure 29 Excision lines test by PCR 
(A) PCR design, primers spanning insertion site should produce a product of 
433 bp for wt chromosome, meaning that excision was precise. (B) PCR was 
done on genomic DNA and resolved on agarose gel. Lines 1 and 2 are 
imprecise while lines 4 and 5 are precise.  
 
If the phenotype is caused by reduced TOR signaling, as is seen in cell 
culture, then we would expect fat levels to be rescued via genetic 
manipulations that restore TOR activitiy.  To test this, we used UAS-RhebAV4 
allele ((Patel et al., 2003)) to express Rheb in the MAP4K3 mutant 
background. Indeed, reduced levels of fat could be rescued by ubiquitous 
expression of Rheb, using UAS-Gal4 system that allows heterologous 
expression of a gene of interest in the tissue-specific manner. Driving 
expression under control of UAS (Upstream Activating Sequence) promoter 
with a Gal4 transcription factor under the control of daughterless promoter 
(ubiquitous, low level) resulted in a partial rescue of reduced fat levels (Figure 
28D). This indicated that increasing TORC1 activity can restore the fat defect 
in MAP4K3 mutants at least partially. At the same time driving Rheb in a wt 
background does not make flies fatter indicating that MAP4K3 is a “sensitized” 
background and the rescue is specific. To assess the remaining minimal 
levels of MAP4K3 we made use of the deficiency deleting the gene entirely 
(Df(2R)Exel6069). Heteroallelic combination of MAP4K3/ Df(2R)Exel6069 
should have 2-fold less MAP4K3 mRNA and still had the same fat levels as 
MAP4K3 mutant. This argues that the residual level of MAP4K3 are not 
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substantial, so that reducing it even more does not worsen the phenotype 
(Figure 28E). 
Insulin regulates glucose and fat metabolism in mammals. Insulin-Like 
Peptides (ILPs) have the same function in Drosophila. In MAP4K3 mutant flies 
ILP levels are dramatically decreased (Figure 30). ILPs are responsive to 
nutritional conditions and go down upon starvation, suggesting that MAP4K3 
mutant animals behave as if starved, even though nutrients are available. 
Rheb expression rescues ILP levels to some extent for two of the three 
measured ILPs, supporting the idea that reduced ILPs are consequences of 
low fat storage. 
 
 
Figure 30 Insulin-like peptides are low in MAP4K3 mutants and can be 
partially rescued by Rheb 
Quantitative PCR of Insulin-like peptides (ILP) in control, MAP4K3 mutant and 
daGal4>>UAS-Rheb rescue flies. 
 
4.2.3. Overexpression of MAP4K3 
 
Next we tested the effect of overexpression of MAP4K3, using a EP(2)2445 
insertion containing  UAS promoter, that can be used to activate expression 
with different Gal4 drivers.  
Ubiquitous Gal4 drivers with strong expression turned out lethal with 
expression levels correlating well with lethality (Figure 31A). tubGal4 (tubulin) 
had highest expression and lethal at early larval stage, actGal4 (actin) had 
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weaker expression and partial lethality (~50-60%), while daGal4 
(daughterless) had low expression similar to the wt and no lethality. Other 
weak drivers armGal4 (armadillo) and hsGal4 (heatshock) at 25 degrees also 
did not show lethality. These data imply that too much MAP4K3 product is 
deleterious for organism development.  
 
 
Figure 31 Overexpression of MAP4K3 with different Gal4 drivers 
(A) RNA from adult flies, ectopically expressing sMAP4K3 using the EP2445 
P-element insertion, was isolated and quantitative PCR on MAP4K3 
performed. (B) EP2445 driving in the posterior compartment of the wing using 
enGal4 makes it smaller. Posterior compartment area was measured and 
normalized to anterior part. p = 6.7*10-5, n=5. 
 
Overexpression with Gal4 driver driving expression in the specific tissues or 
domains such as eye (eyelessGal4) or wing (apterousGal4, nubbinGal4, 
patchedGal4) did not produce dramatic phenotypes. apGal4 is expressed in 
the dorsal part of the wing and resulted in slightly upwards curved (curly) 
wings but it was not highly penetrant. MAP4K3 ectopic expression in the 
posterior half of the wing, using engrailedGal4 (enGal4) resulted in the 
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decreased area of the expression compartment, suggesting reduced growth 
rate and/or size of the cells (Figure 31B). This could be the result of dominant-
negative action on TORC1 by titrating out TORC1 activators (e.g. Rag 
GTPases, see below). enGal4 also caused posterior cross vein branching in 
some flies. 
 
4.2.4. Genetic interactions 
 
Since MAP4K3 was shown to affect TORC1 activity in cells, we tested if it can 
do so in the context of the whole organism. TSC2 mutant flies die at the early 
larval stage, presumably because of excess TOR activity (Ito and Rubin, 
1999). We tried to rescue this lethality by combining this gig192 mutation with 
MAP4K3 mutant, which supposedly should decrease TOR activity. However, 
removing MAP4K3 did not rescue gig192 TSC2 mutant.  
Rheb mutation causes developmental arrest and lethality at the first instar 
larval stage, because of the reduced TOR activity (Saucedo et al., 2003). We 
tried increasing TOR activity by overexpressing MAP4K3 in the Rheb mutant 
background (Rhebdelta1/delta2). MAP4K3 overexpression by driving EP(2)2445 
with daGal4 could not rescue Rheb lethality. This is not very surprising, given 
that this allelic combination can only be rescued to the 2nd instar by 
introducing Rheb itself back (hsGal4>>UAS-Rheb (Saucedo et al., 2003)). 
MAP4K3 mutant does not affect the phenotype of chico mutant (Drosophila 
ortholog of IRS), which is small size flies (Bohni et al., 1999). 
Overexpression of Rheb in the dorsal side of the wing with apGal4 causes the 
wings to curve down, because Rheb promoting cell growth via TORC1 makes 
the area of the dorsal side larger, thus resulting in curved down wings. 
MAP4K3 mutant background cannot alter this phenotype.  Taken together 
these results are suggesting that in the context of the whole organism 
MAP4K3 doesn’t affect TORC1 or its effect on TORC1 is not large enough to 
modify phenotypes of other genes in the Insulin/TOR pathway. 
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4.2.5. MAP4K3 molecular mechanism   
 
To address the mechanism of action of MAP4K3 in the whole animal, we first 
turned to TOR, since based on cell culture data MAP4K3 is mediating amino 
acids signaling to TORC1. Western blot analysis of fly protein extract to 
assess TORC1 activity in the mutant did not provide an insight into status of 
TORC1. An example of the Western blot is shown in Figure 32. TOR activity 
as measured by 4EBP and S6K phosphorylation for control (w1118) and 
MAP4K3 mutant flies, grown under controlled conditions. 4EBP 
phosphorylation was variable from sample to sample.  
 
 
Figure 32 TOR activity in MAP4K3 mutant 
(A) 10 male flies were homogenized in sample buffer and proteins were 
separated on SDS-PAGE and detected with indicated antibodies. (B) Pre-
wandering 3rd instar larvae were dissected and fat body proteins were 
resolved on the SDS-PAGE and detected with indicated antibodies. Note 
variability in the signal of phospho 4EBP antibody. 
 
 After several trials we concluded that TORC1 activity is variable in the 
animals, it does not seem to be reduced, as might be expected from cell 
culture data. One possible reason for difficulties to define TORC1 activity is it 
may be different in different tissues and looking at the whole animal level is 
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not informative. Since MAP4K3 mutants are deficient in fat metabolism and fat 
body is the organ regulating fat, we asked whether TOR activity is altered in 
the fat body of the mutant pre-wandering 3rd instar larvae. Unfortunately, 
these results were also not informative, Western blot on fat body protein 
extracts worked badly; total 4EBP antibody failed to detect endogenous levels 
of 4EBP, phospho-specific 4EBP antibody varying levels in the mutant, while 
phospho-S6K antibody showed similar levels of active S6K in both wt and 
mutant (Figure 32B). Although not conclusive, these results do not support an 
idea of decreased TOR activity in the MAP4K3 mutant. We decided to focus 
our attention on genetic interactions that would provide a clue about TOR 
status in MAP4K3 mutants. 
Recent reports connecting MAPK signaling and TORC1 raise the possibility 
that MAP4K3 may affect TORC1 through one or more of the MAP kinases 
branches. This is quite a complex question as there are 4 main branches of 
MAP kinases with partially overlapping inputs and outputs. MAP4K3 has been 
reported to activate JNK pathway (Diener et al., 1997; Shi and Kehrl, 1997), 
ERK has been implicated in signaling to TORC1, so I tested if these pathways 
are also affected by MAP4K3 in Drosophila. MAP4K3 knock-down by dsRNA 
in S2 cells resulted in the decrease in ERK and JNK activities, while MAP4K3 
expression promoted their phosphorylation on activating residues (Figure 
33A). Total protein for ERK and JNK was changing in a similar fashion, 
suggesting that the total protein levels also change, if the loading is equal. 
Loading is actually affected with knock-down having less total protein and 
MAP4K3 expression more, because knocking down MAP4K3 is decreasing 
cell growth and expressing it drives growth, so there are more cells in the well. 
Still comparing differences in loading from a background bands with 
differences in active ERK (pT202/204 ERK1/2 ) and active JNK (pT183/185 
JNK),  it is likely that MAP4K3 is able to regulate ERK and JNK activity and 
possibly protein levels in S2 cells. These results point out a possible 
mechanism by which MAP4K3 may affect TORC1, namely by modulation of 
TORC1 signaling through MAPK ERK and/or JNK branches.  
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Figure 33 MAP4K3 is able to regulate ERK and JNK and bind Rag 
GTPases 
(A) S2 cells were incubated with dsRNA against MAP4K3 or transfected with 
pMT-MAP4K3. Cell lysates were analyzed by Western blot with antibodies 
against phosphorylated (active) and total ERK and JNK. Loading shows a 
non-specific background band for phosphorylated antibodies as a loading 
control. (B) S2 cells were transfected with indicated DNAs. Lysates( Input) 
and FLAG -immunoprecitates were analysed for levels of specified proteins. 
Arrows indicate two Rags proteins, star designates background band. GFP 
was used as a control. 
 
Domain structure analysis for MAP4K3 reveals that in addition to kinase 
domain it contains a C-terminal Citron domain, which is a putative small 
GTPase interactive domain. This raised a possibility that MAP4K3 may 
interact with GTPases. Rheb is a small GTPase regulating TORC1. We tested 
if the MAP4K3 can interact with Rheb in S2 cells by co-immunoprecipitation 
but could detect no interaction between the two (data not shown). Another 
possibility is that newly discovered Rag GTPases, involved in amino acid 
signaling to TORC1 (Kim et al., 2008; Sancak et al., 2008), are interacting 
partners for MAP4K3. Drosophila Rags homologs CG11968 and CG8707 
have been cloned and expressed in S2 cells and tested their interaction with 
MAP4K3 by immunoprecipitation. Immunoprecipitated Rags complexes 
contained co-expressed MAP4K3 as shown in Figure 33B. This interaction 
suggest that MAP4K3 may regulate Rags either by changing their activity or 
their binding to TORC1.  
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Taken together, the results from Drosophila mutant of MAP4K3 indicate that 
MAP4K3 is not essential for viability, but important for optimal growth and 
metabolism. Surprisingly, one of its main phenotypes manifests in fat stores of 
the animal, highlighting the close connection between nutrient sensing and 
storage of fat as a main energy reserve. This is dependent on TORC1 activity 
because stimulating TORC1 can rescue the phenotype. Growth is affected as 
well, since it strongly depends on the availability of nutrients.  
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4.3. Discussion 
 
4.3.1. MAP4K3 regulates growth  
 
TOR signaling is critical regulator of growth. Flies lacking TOR arrest their 
growth and die as early stage larvae (Oldham et al., 2000; Zhang et al., 
2000). Growth regulation by dTOR is primarily mediated by dS6K, since its 
overexpression can rescue TOR mutants. Phenotypes of TOR deficient 
animals are reminiscent of amino acids starved animals. MAP4K3 was 
proposed to function as a amino acid sensor, based on cell culture data and 
the fact that its activity is stimulated by amino acids. Our data support this 
notion, because in the organism MAP4K3 is regulating growth. MAP4K3 
mutants develop slower than controls and have partial lethality at the pupal 
stage. In addition their viability is compromised as evident from lethality during 
the first 2 days.  Furthermore, they display a small but highly significant 
reduction in wing size, indicating that their growth ability is compromised. 
Under conditions of low nutrients (20% of normal food), TOR signaling is 
reduced and growth is delayed. Interestingly, when TOR signaling does not 
need to be fully activated mutant and control animals develop at the same 
rate, supporting the idea that MAP4K3 is required under rich nutrient 
conditions to promote optimal growth. 
In general phenotypes of MAP4K3 mutants are quite mild, compared to those 
of dTOR itself(Oldham et al., 2000; Zhang et al., 2000), dS6K (Montagne et 
al., 1999) or Rags (Kim et al., 2008), a new component in nutrient signaling, 
identified recently. All of these cause a growth arrest during the larval stages, 
as does amino acid starvation itself. Thus MAP4K3 is probably not a critical 
component of the amino acids sensing but rather has a modulatory role, 
providing maximal TORC1 activation under favorable conditions. Alternatively, 
we cannot exclude the possibility that the mutant we have analized is not a 
complete loss of function and the remaining 1 percent of mRNA is enough to 
provide residual function of the gene. The fact that further reducing the levels 
of MAP4K3 by half using a deficiency does not worsen the phenotype argues 
against this possibility.  
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MAP4K3 function, although not crucial for individual animal viability, has an 
important function for species survival. This is elegantly demonstrated by the 
fact that l(2)SH1261 insertion was isolated in a screen for mutations on 
chromosome 2  and was reported to be lethal (Oh et al., 2003). This 
happened most probably because under normal culturing conditions with 
competition between individual animals, homozygous mutants do not survive 
because they are slower and weaker heterozygous pals. In evolutionary 
sense, a gene providing a small competitive advantage (for example shorter 
developmental time) can be as important as a gene absolutely required for 
viability of the organism. In a real world, outside research lab, with fierce 
competition for limited resources, it is only a matter of a few generations until 
the progeny carrying a mutation in such a gene is extinct. That is probably the 
reason why these, seemingly “dispensable”, genes are conserved in evolution 
just as “viability” genes. 
4.3.2. MAP4K3 affects fat metabolism  
 
Growth is metabolically expensive process, a cell has to generate biomass 
and this requires energy and building blocks for protein and membrane 
synthesis (Edgar, 2006). Thus it is not very surprising that TOR as a regulator 
of growth also affects and is affected by metabolism. Both classical TOR 
effectors S6K and 4EBP have metabolic phenotypes in knockout animals: 
mutant S6K1 mice are protected from diet-induced obesity (Um et al., 2004), 
while 4EBP1 knockout mice are lean, hypoglycemic and have altered fat 
metabolism (Tsukiyama-Kohara et al., 2001). In addition, fly 4EBP mutants 
are starvation sensitive and lose fat faster under starvation (Teleman et al., 
2005a). Low TOR activity in hypomorphic dTOR allele has been shown to be 
associated with reduced fat levels and reduce glucose levels (Luong et al., 
2006).  
Insulin regulates carbohydrates and lipid metabolism in response to nutrients. 
Although glucose homeostasis is most often associated with insulin, it is only 
one of many insulin-regulated processes. These also include synthesis and 
storage of fat, protein synthesis, and non-metabolic processes such as cell 
growth and differentiation (Biddinger and Kahn, 2006). Different tissues 
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respond in a different way to insulin. In response to high levels of glucose (fed 
conditions) insulin promotes glucose uptake by muscles. Liver responds by 
increasing glycogen synthesis and decreasing gluconeogenesis. Adipose 
tissue responds by promoting lipogenesis for fat storage and reducing 
lypolysis, that releases free fatty acids. Thus phenotypes of loss of function 
studies in the whole organism are difficult to predict and the outcome depends 
on the combination of effects from different tissues. For example insulin 
receptor substrate mutant chico flies are fat (Bohni et al., 1999), while 
hypomorphic dTOR mutants are lean (Luong et al., 2006). Systemic reduction 
in the insulin signaling has been associated with elevated lipids levels (Bohni 
et al., 1999; Broughton et al., 2005), while insulin signaling reduction in 
adipose tissue leads to the opposite, as is the case for FIRKO (fat insulin 
receptor knockout) mice (Bluher et al., 2002). 
MAP4K3 mutants are lean and this phenotype can be rescued by driving 
Rheb, indicating that reduced TORC1 activity accounts for this phenotype. Fat 
body is the main site of adipose tissue and fat metabolism regulation. It is 
plausible that low TOR activity in fat body could mimic starvation, leading to 
inhibition of lypogenesis and activation of lypolysis, resulting in low fat stores. 
MAP4K3 mutants’ phenotype are in accordance with low TOR activity and 
show similarity to FIRKO mice and flies with low TOR. Low ILPs are also 
consistent with low glucose reported for flies with reduced TOR (Luong et al., 
2006). Furthermore, rescue of the fat phenotype by increasing TOR with Rheb 
overexpression is accompanied by a partial rescue of ILP levels. This 
suggests that low ILPs in the MAP4K3 mutant are the consequences of low 
fat levels and when those are normalized ILPs also recover. Alternative 
scenario where the the phenotype is caused by a defect in ILP production is 
not likely, because flies with ablated ILP producing cells are not lean but 
rather have slightly higher lipids (Broughton et al., 2005). 
4.3.3. TOR activity status and possible mechanism 
 
How is MAP4K3 acting in molecular terms? I tried to approach this question 
with biochemical and genetic approaches. Biochemical data from mutant flies 
did not provide a definitive answer as TORC1 activity, measured by 
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phosphorylation of 4EBP and S6K was variable (Figure 32). Although variable 
it did not appeared to be reduced, as might be expected from cell culture data 
(Findlay et al., 2007). It was also possible that tissue specific effect of 
MAP4K3 reduction was not strong enough to be detected in the whole animal 
extracts. Fat body is a good candidate for tissue specific effects of MAP4K3, 
because it is the organ, whose function is to store fat and regulate fat 
metabolism (Colombani et al., 2003). We didn’t see a change in TOR activity 
in fat body, although the analysis was complicated by the absence of total 
S6K antibody and poorly working total d4EBP antibody. Interestingly, TOR 
activity is also not changed in chico mutants (measured by S6K activity). 
Moreover, S6K protein levels are increased in dTOR mutant or by starvation, 
suggesting that S6K protein level in addition to activity are regulated by amino 
acids (Oldham et al., 2000). All this makes interpretation of biochemical data 
more difficult, especially given the lack of total S6K antibody. 
Since I could not obtain clear data from biochemistry, I used genetic approach 
to ask whether MAP4K3 can interact with other genes in the Insulin/TOR 
pathway. Most of the genetic interaction I tried (Rheb, TSC2, chico) did not 
succeed. This could mean that MAP4K3 does not change TOR activity in vivo 
or alternatively that its effect on TOR is not as strong as those of the other 
genes tested. Indeed the phenotypes of Rheb and TSC2 genes are lethality 
and chico also has a strong effect on survival and size, while MAP4K3 
phenotypes are relatively mild. Thus it may not be surprising that MAP4K3, 
whose effects are more modulatory in nature cannot  change the dramatic 
phenotypes of critical TOR regulators. On the other hand, Rheb expression 
can efficiently rescue lean phenotype of MAP4K3 mutants. This suggests that 
most of the phenotypic effect of MAP4K3 mutant comes from reduced TOR 
activity. It would be interesting to see if driving Rheb in the fat body can 
rescue MAP4K3 phenotype. 
I have started to look into the mechanism of acton of MAP4K3 but did not 
have time to address this issue in detail. From belonging to the family of MAP 
kinase regulator it is tempting to speculate that MAP4K3 can affect TOR 
through activation of one or more branches of MAPK signaling. Indeed, initial 
experiments showed that MAP4K3 expression can activate ERK and JNK 
kinases and possibly affect their protein levels. This fits very well together with 
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recent report implicating ERK and p38 MAPK signaling branches in amino 
acid signaling to S6K (Casas-Terradellas et al., 2008). In addition ERK-
activated RSK kinase has been shown to regulate TORC1 activity directly by 
activating phosphorylation on raptor (Carriere et al., 2008).   
Another possible avenue for exploring mechanistic mode of action of MAP4K3 
is to look for possible interacting proteins. Since MAP4K3 has a conserved 
GTPase regulating domain, it may interact with a small GTPase. We  could 
not detect interaction with Rheb, suggesting Rheb is not an effector of 
MAP4K3, although not all transient interactions are detectable by 
immunoprecipitation. Rag GTPases have been independently identified by 
two groups and established as mediators of amino acids sufficiency in 
mammalian cells and Drosophila (Kim et al., 2008; Sancak et al., 2008). Rag 
GTPases function as a heterodimer and can bind to TORC1 and regulate its 
activity towards S6K following amino acids stimulation. Four Rag proteins 
exist in mammals (RagA, RagB, RagC, and RagD). RagA and RagB are very 
similar to each other and are orthologs of budding yeast Gtr1p, whereas 
RagC and RagD are similar and are orthologs of yeast Gtr2p. In yeast and in 
human cells, the Rag and Gtr proteins function as heterodimers consisting of 
one Gtr1p-like (RagA or RagB) and one Gtr2p-like (RagC or RagD) 
component (Hirose et al., 1998; Nakashima et al., 1999; Sekiguchi et al., 
2001). Amino acids stimulate binding of Rags to raptor and promote TORC1 
activity. Our preliminary data show that MAP4K3 can interact with Rags. This 
strongly suggests that it can modify their activity either by regulating their 
interactions with raptor and thus TORC1 or by regulating their GTPase 
activity. We are in the process of testing this hypothesis. 
4.3.4. Metabolism and growth, a close relationship 
 
MAP4K3 is a protein conserved in mammals and it is interesting if its function 
is also conserved. This is likely to be the case because mammalian cell 
culture work has shown human MAP4K3 also regulates TORC1 and cell size. 
These data agrees well with this work, but metabolic effects of MAP4K3 will 
have to be confirmed in a mammalian system. This is of interest because of 
the therapeutic potential of MAP4K3 as a metabolic regulator.  
 91 
In general, this work exemplifies the utility of whole organism studies and 
complementarity of cell culture and model organism studies. It would be very 
difficult to discover metabolic phenotypes in the cell culture system. I would 
also like to argue that metabolic aspect of the MAP4K3 phenotype is a causal 
one and the growth aspect is a consequence of the metabolic deficiency. 
Growth is a final result that is easy to measure and is by its nature a very 
convenient visual phenotype. However, it is dependant on adequate supply of 
building blocks and energy to fuel accumulation of biomass. MAP4K3 mutants 
have a metabolic defect that does not allow them to accumulate normal 
amounts of adipose tissue and this may be the reason why they have mild 
growth defects. The literature presents TOR as a critical controller of growth 
and its role in metabolism is also well established (Harris and Lawrence, 
2003; Hay and Sonenberg, 2004; Wullschleger et al., 2006). Growth and 
metabolism are two processes regulated by TOR, but the link between them 
is not always evident. Although TOR is a “classical” growth regulator, the 
exact mechanism of growth control remains elusive. TOR controls translation 
through 4EBP and ribosome biogenesis through S6K, thus regulating protein 
synthesis that is required for growth. However, looking closer at the data 
reveals some interesting facts. Firstly, 4EBP loss of functon studies show that 
growth is normal in flies and mice lacking 4EBP; instead metabolism is 
deregulated (Teleman et al., 2005a; Tsukiyama-Kohara et al., 2001). 
Moreover, recently the theory of TOR control of translation of 5′ tract of 
oligopyrimidine (TOP) mRNAs, thought to be important for growth, was 
challenged (Pende et al., 2004; Ruvinsky et al., 2005). In S6K1/S6K2 double 
knockout mice cells 5′ TOP mRNAs were still responsive to mitogen signals 
and S6 protein was still phosphorylated on some residues by a MAPK 
pathway (Pende et al., 2004). Moreover in mice with knock-in of S6 protein 
with all its S6K phosphorylation sites mutated to alanines, translation of 5′ 
TOP mRNAs is not affected. Interestingly, these mice in addition to growth 
defects suffer from diminished levels of pancreatic insulin, hypoinsulinemia, 
and impaired glucose tolerance (Ruvinsky et al., 2005). These results taken 
together with our findings in the MAP4K3 mutant flies suggest a general 
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model of metabolism deregulation underlying growth defects. This hypothesis 
can be put to the test by future studies. 
In summary, this work identifies the physiological function of MAP4K3 in 
modulating growth during development and regulation of fat metabolism in 
Drosophila. We propose that it enables optimal activation of TORC1 in 
response of sufficient nutrients levels. Molecular mechanism most likely 
involves modulation of TORC1 activity and may involve inputs from MAPK 
pathway and/ or Rag GTPases. Given a role of MAP4K3 in fat metabolism 
and growth it may represent a new target for treatment of metabolic diseases 
such as obesity and diabetes and possibly for growth deregulated conditions 
such as cancer. It remains to be seen if MAP4K3 role in fat metabolism and 
growth is conserved to mammals as it may represent a new target for 
treatment of metabolic diseases and cancer.  
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5. Conclusions 
The work presented in this thesis attempts to improve our understanding of 
how cells sense and coordinate external cues to grow and maintain energy 
homeostasis in a changing environment. To this end I tried developing a new 
tool to visualize TORC1 activity in cells and characterized an in vivo function 
of a new component in a nutrient sensing pathway in Drosophila. 
Developing a FRET-based probe for TORC1 activity proved to be a 
challenging task. Although a number of approaches have been tried, including 
intramolecular and intermolecular FRET, several cell lines tested and various 
FRET detection methodologies implemented, we could not obtain a working 
FRET probe. The major difficulty I encountered, was abolishment of the 
biological regulation of the FRET probe compared with the regulation of the 
endogenous protein, because of the fusion to relatively large GPF domain/s. 
This is a general problem of introducing non-natural fusion protein into cells 
but I managed to overcome this obstacle by empoying an in vivo labeling 
method utilizing a small tag. This probe was shown to be functional but 
produced no reliable FRET signal, when introduced into cells, even though 
several alternative fluorophore positions were tested. The reasons for FRET 
absence could include unfavorable orientation of fluorophores, differences in 
brightness or concentrations of the interacting partners. In conclusion, 4EBP1 
does not seem to be a good starting point for FRET probe development, 
because of its small size and sensitivity to fusions and also because of lacking 
of defined three-dimensional structure that would allow rational probe design. 
MAP4K3 mutant analysis in Drosophila was performed and its functional 
significance on the level of the whole organism assessed. MAP4K3 is not 
crucial for individual animal viability, but it affects growth and development. 
Lacking MAP4K3 makes animals grow slower and attain smaller final size. 
This is most probably because the mechanism sensing nutrients is 
compromised, which manifest itself in reduced fat stores and altered insulin-
like peptide levels. This deficiency can be rescued by increasing TORC1 
activity, confirming a role of TORC1 as a main effector of MAP4K3. Molecular 
mechanism of MAP4K3 action is not yet clear but it may involve modulation of 
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MAP kinase signaling or function of Rag GTPases. These findings confirm a 
role for MAP4K3 in nutrients sensing and control of growth and metabolism 
and lay a foundation for further investigation of its function under normal and 
disease conditions. 
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6. Outlook 
The ultimate level of understanding a complex biological system is its 
modeling in silico, which provides explanation of experimental data and 
prediction for manipulations. For modeling of TOR pathway we need more 
data that has to be quantitative and also dynamic. FRET sensors supply data 
in a temporal and spatial resolution, which is difficult to obtain otherwise. My 
attempts to generate a TOR FRET probe demonstrate many challenges that 
are associated with this approach. Nevertheless, many options for future 
development still exist. Methods for FRET detection are improving as well a 
palette of genetically encoded and synthetic fluorophores (Chudakov et al., 
2005). TOR substrates other than 4EBP can be used as a starting point of 
probe development, one candidate could be S6K.  
Alternative strategies can be considered, for example Rags proteins are small 
GTPases and their binding to TOR  is dependent on GTP loading (Kim et al., 
2008; Sancak et al., 2008), (unlike Rheb, whose binding is not dependent on 
GTP/GDP). Lots of experience has been accumulated for designing FRET 
probes for small GTPases (Aoki et al., 2008; Itoh et al., 2005; Mochizuki et al., 
2001; Yoshizaki et al., 2003), which can be used to generate Rags-based 
probes.  
MAP4K3 function analysis opens a lot of possibilities to extend the data 
presented here. More phenotypic data can be collected to characterize 
specific defects of the phenotype. Autophagy is among the most conserved 
phenotypes of amino acid starvation and it has not yet been looked at. More 
complete metabolic analysis (levels of sugars, etc) should be performed to 
figure out what is the mechanism of fat reduction in MAP4K3 mutants. Given 
conservation of MAP4K3 protein it is interesting if it controls metabolism in 
mammals. 
Molecular mechanism also warrants further investigation. How MAP4K3 fits in 
the MAPK network and what is the significance of MAPK signaling in amino 
acid stimulation of TORC1 and its downstream effectors? Interaction with Rag 
GTPases is another lead. It has to be clarified how MAP4K3 affects Rags 
function. Additionally, MAP4K3 is a kinase, so what is its substrate/s? Is it 
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itself regulated by phosphorylation like many kinases in signaling cascades? 
How exactly do amino acids affect MAP4K3 activity? In other words there is 
still a lot to do   
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7. Materials and Methods 
7.1. Chemicals and solutions 
Standard chemicals were purchased from Sigma-Aldrich AG (Steinheim, 
Germany) or Merck (Darmstadt, Germany).  
Kits for DNA purification were purchased from Qiagen GmbH (Hilden, 
Germany).  
Competent cells (XL1-Blue) were prepared by Eva Loeser in Cohen lab.  
All buffers and chemical solutions, unless otherwise stated were prepared 
with sterile double distilled water, according to the standard molecular biology 
protocols (Maniatis et al., 1989), and filter sterilized. 
7.2. Molecular biology and cloning 
DNA primers and oligonucleotides were purchased from Sigma-Aldrich AG 
(Steinheim, Germany). Enzymes for recombinant DNA work were purchased 
from New England Biolabs (Ipswich, USA) or Fermentas (St. Leon-Rot, 
Germany).  
Kits for purification of plasmid DNA, as well as for purification of PCR and 
restriction products, were used according to the protocol of the supplier. 
Restriction and ligations for cloning were performed using reagents from 
New England Biolabs and standard molecular biology protocols (Maniatis et 
al., 1989). DNA sequencing was performed by EMBL genomics core facility.  
7.3. Plasmids 
 
Plasmids described in this thesis are listed in Table 7.1, including source of 
the original vector backbone. Restriction sites used for cloning the insert are 
indicated, where necessary.  
For FlAsH labeling tetracystein tag was introduced into 4EBP1 coding 
sequence either at N- or C-terminus by PCR using oligos containing tag and 
the PCR product was cloned into pcDNA3 vector. All final constructs were 
verified by sequencing. A list of oligonucleotides, used for cloning and PCR is 
provided in the Appendix.  
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Table 7.1 List of plasmids generated in this thesis 
 
 
 
 
 
 
Name Vector backbone Insert 
Restriction sites used for 
cloning 
Original Vector 
Backbone Source 
pBB14 pcDNA3.1 ECFP-Citrine Starting point for cloning from  Bastiaens  lab, EMBL 
pBB15 pcDNA3.1 ECFP Starting point for cloning from  Bastiaens  lab, EMBL 
pBB16 pcDNA3.1 monoECFP Starting point for cloning from  Bastiaens  lab, EMBL 
pBB18 pcDNA3.1 ECFP-h4EBP1 made by removing Citrine from pBB19 
from  Bastiaens  lab, 
EMBL 
pBB19 pcDNA3.1 ECFP-h4EBP1-Citrine BamHI- BglII 
from  Bastiaens  lab, 
EMBL 
pBB20 pcDNA3.1 h4EBP1-Citrine made by removing ECFP from pBB19 
from  Bastiaens  lab, 
EMBL 
pBB21 pcDNA3 heIF4E EcoRI-NotI Cohen lab plasmid collection 
pBB24 pEYFP-Clontech YFP-dummy-GFP
2 Starting point for cloning from  Schultz  lab, EMBL 
pBB25 pEYFP-Clontech 
mYFP-dummy-
mGFP2 Starting point for cloning 
from  Schultz  lab, 
EMBL 
pBB28 pBB24 h4EBP1 NcoI-BamHI from  Schultz  lab, EMBL 
pBB29 pBB25 h4EBP1 NcoI-BamHI from  Schultz  lab, EMBL 
pBB42 pcDNA3 4Cys-h4EBP1 EcoRI-NotI Cohen lab plasmid collection 
pBB43 pcDNA3 h4EBP1-4Cys EcoRI-NotI Cohen lab plasmid collection 
pBB47 pBB15 heIF4E EcoRI-XhoI from  Bastiaens  lab, EMBL 
pBB48 pBB15 heIF4E KpnI-BamHI from  Bastiaens  lab, EMBL 
pBB49 pBB16 heIF4E EcoRI-XhoI from  Bastiaens  lab, EMBL 
pBB50 pBB16 heIF4E KpnI-BamHI from  Bastiaens  lab, EMBL 
pBB51 pUAST MAP4K3 NotI-XhoI Cohen lab plasmid collection 
pBB53 pMT3b MAP4K3 NotI-SalI Cohen lab plasmid collection 
pBB55 pOT2 MAP4K3 cDNA EcoRI-XhoI 
Drosophila Genomics 
Resource Center 
(DGRC) 
pBB59 pMT3b MAP4K3-HA HA-tag is in NheI site Cohen lab plasmid collection 
pBB60 pMT3b dRagA NotI-XhoI Cohen lab plasmid collection 
pBB61 pMT3b FLAG-dRagA FLAG is in NotI Cohen lab plasmid collection 
pBB62 pMT3b dRagC NotI-XhoI Cohen lab plasmid collection 
pBB63 pMT3b FLAG-dRagC FLAG is in NotI Cohen lab plasmid collection 
 99 
7.4. PCR, RT-PCR and quantitative real-time PCR 
 
Genomic DNA extraction for l(2)SH1261 P-element excision mapping:  
Collect 10 adult flies in an eppendorf tube kept on ice. Crush flies in 100 µl 
of Homogenizing Buffer (0.1 M Tris-HCl pH9.0, 0.1 M EDTA, 1 % SDS) using 
plastic pestle until no more large pieces of cuticle can be seen. Incubate 
samples at 65°C for 30 minutes, and then add in 22.5 µl of 5 M KOAc and 
chill samples on ice for 30 minutes. Centrifuge samples for 10 minutes at 
4°C and transfer supernatant to a new eppendorf tube. Add in 60 µl of 
Isopropanol and incubate for 5 minutes at room temperature. Centrifuge 
again for 5 minutes at room temperature. Wash pellet with 1 ml of 70 % 
EtOH and air-dry pellet at room temperature. For PCR reactions afterwards, I 
resuspended pellet in 50 µl of sterile distilled water instead of TE Buffer (10 
mM Tris adjusted to pH8.0 with HCl, 1 mM EDTA). I also added in DNase-
free RNase A at a final concentration of 10 µg/ml to eliminate ribosomal 
RNA. Heating up to 65°C may help dissolve the pellet if necessary. Measure 
concentration in Nano-Drop spectrometer to assess the yield. Store DNA 
samples at -20°C.  
  
7.4.1. PCR reaction 
 
The PCR reaction was carried out in volume of 25 µl and contained 1 µl of 
extracted genomic DNA as amplification template, 1.25U Taq DNA 
polymerase (Roche), 1x PCR Buffer containing MgCl2 (Roche), 0.2 mM 
dNTPs (PCR grade, Roche), 0.4 µM of forward and reverse primers, and 
sterile distilled water. The PCR reaction was running on Thermal Cycler 
(PTC-200, MJ research) according to the following program:  
 
Step 1 94°C for 3 minutes  
Step 2 94°C for 30 seconds  
Step 3 55 or 60°C for 30 seconds (depend on the Tm values of primers)  
Step 4 72°C 30 seconds to 1 minute (depend on the length of the product)  
Step 5 Repeat step 2-4 for 29 times  
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Step 6 72°C 10 min  
Step 7 End at 4°C  
 
The amplified products were separated by electrophoresis on 0.8 – 1.5 % 
agarose gel and visualized by Ethidium Bromide staining and UV light.   
 
7.4.2. RNA isolation  
 
Collect 5-10 adult flies or larvae into 1.5 ml eppendorf tube and keep on ice. 
Homogenize samples with 200 µl of TRIzol reagent (Invitrogen) first with 
plastic pestle until no more large pieces of cuticle can be seen. Rinse the 
pestle with additional 800 µl of TRIzol and kept samples at room 
temperature for 5 minutes. For cell sample, lyse by pipetting cells up and 
down several times in 1 ml of TRIzol and keep it standing for 5 minutes at 
room temperature. Then, add in 200 µl of Chloroform and vortex samples for  
15 seconds. Incubate samples at room temperature for 15 minutes before a 
centrifugation at 14000 rpm at 4°C for 15 minutes. I carefully took the 
aqueous phase (top layer) into a new eppendorf tube and added in 500 µl of 
Isopropanol for precipitation RNA. Incubate samples at room temperature 
for 10 minutes, followed by a 15 minutes centrifugation at 4°C. Wash pellet 
with 75 % Ethanol (in RNase-free water) and dry pellet at room temperature 
for 15 minutes. Dissolve pellet in 50 µl of RNase-free water. Heating up to 
60°C helps dissolve RNA into water if necessary. Store RNA samples at -
80°C.  
7.4.3. First-strand cDNA synthesis – Reverse Transcription 
  
First-strand cDNA for PCR reaction was synthesized by reverse 
transcriptase using SuperScript II or III first-strand synthesis system 
(Invitrogen). Mix 1 µg RNA with oligo(dT) and dNTPs in a volume of 10 µl and 
heat up to 65°C to denature secondary structures of RNA, and then place 
them on ice for 1 minute. Prepare reaction mixture composed of reaction 
buffer, MgCl2, DTT, RNase inhibitor, and SuperScriptTM II RT and add 10 µl 
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of reaction mixture to each RNA/primer mix. Incubate samples at 42°C for 50 
minutes. Terminate the reactions at 70°C for 15 minutes, and then chill 
them on ice for the next procedure or store them at -20°C.  
  
7.4.4. PCR reaction on cDNA 
  
As described in Section 7.4.1, only the PCR reaction was carried out using 2 
µl of synthesized cDNA as amplification template instead.  
 
7.4.5. Quantitative real-time RT-PCR  
 
RNA isolation and first-strand cDNA synthesis: 
RNA isolation and cDNA synthesis were performed as described in 
sections 7.4.2 and 7.4.3 for RT-PCR. Because the cDNA:RNA hybrid 
molecule decreases the sensitivity of real-time PCR reaction from cDNA 
templates, I added one more step to eliminate RNA template in cDNA 
samples with RNase H for 20 minutes at 37°C before proceeding to the 
PCR reaction.  
  
Primers used for quantitative real-time RT-PCR 
Primer pairs were designed on Oligo 6.0 software. Several criteria were 
used to select the primers for quantitative real-time PCR: about 20 
nucleotides in length, annealing temperature of 58-60°C, GC content of 20-
80%, in general with no more than two G or C residues among the last five 
bases at the 3’ end. The PCR products had to be 100-150 base pairs long 
to minimize PCR cycle time, and no primer-dimers were predicted to be 
sure that the SYBR green dye incorporation was only due to the specific 
amplicon. If possible, intron spanning primer pairs were designed or one of 
the primer pair was designed on exon junction of the coding sequence by 
spanning 5-7 nucleotides on the next exon at the 3’ end of the oligo so that 
the PCR product is only specific to cDNA template rather than contaminated 
genomic DNA. A primer pair specific to Drosophila ribosomal protein 49 
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(rp49) were used for normalization. Prior to real-time PCR, primer pairs 
were tested by conventional PCR using Drosophila cDNA to confirm that 
only one single amplicon at the right size was produced from cDNA 
template. Standard curves were run for each of the gene-specific primer pair 
to test for their efficiency in real-time PCR.  
 
Real-time PCR 
Real-time PCR is performed by monitoring the progress of the PCR as it 
occurs; therefore data is collected throughout the PCR process, rather than 
at the end of the PCR. It makes use of SYBR Green I dye which binds to any 
double-stranded DNA to detect PCR product as it accumulates during PCR. 
The reaction volume was 25 µl containing 12.5 µl 2X SYBR Green PCR 
Master mix (Applied Biosystems), 250 nM of each gene-specific primer, and 
diluted cDNA template which corresponds to 0.1 ng of the original total RNA. 
Reaction mixtures containing water, instead of the cDNA template, were 
used to check cross-reaction contamination. The reactions were run in a 96 
well plate on an ABI Prism 7000 SDS according to the following program:   
  
Stage Cycle Temperature Time 
1 Hold 50°C 2 min 
2 Hold 95°C 10 min 
95°C 15 sec 
3 40 cycles 
60°C 1 min 
 
Later I used LightCycler®480  (Roche) using the same program and Master 
Mix but the reaction was scaled down to 10 µl. Analysis was done using a 
The LightCycler® 480 Relative Quantification Software. 
 
Quantification of gene expression   
Real-time PCR results were analyzed using the ABI Prism SDS software. 
Firstly, I checked the dissociation curve of each run in order to make sure 
the CT (threshold cycle) was specific to amplicon rather than primer-dimers. 
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Secondly, I manually adjusted the baseline to the beginning of the 
amplification and threshold to the exponential phase of the amplification 
curve. Thirdly, all quantitations were normalized to an endogenous control 
(rp49) to account for variability in the initial concentration of the total RNA. It 
also takes it into account the quality of the total RNA and the conversion 
efficiency of the reverse transcription reaction. Finally, gene expression can 
be measured by the quantification of cDNA converted from mRNA 
corresponding to this gene relative to a calibrator samples. By this relative 
quantification, I could determine the fold change of mutant flies 
(experimental samples) to the wild type flies (calibrator sample) for all the 
normalized target cDNAs levels. 
 
7.5. Western blot 
 
Sample preparation  
For cell samples, cells were lysed in 200 µl of 1x Laemmli Sample Buffer. For 
whole larvae or adults extract, total protein was obtained by crushing 4-10 
larvae or adults in 100 µl of 1x Laemmli Buffer with plastic pestle. Boil 
samples at 95°C for 5 minutes and load 10 µl in SDS-polyacrylamide gel.  
Tissue samples were obtained by dissecting of fat body in cold Drosophila-
SFM medium (Gibco) prior to lysing in 50 µl of Lysis Buffer. Fat body samples 
were lysed by pipetting several times in Lysis Buffer on ice. Usually 10µl were 
loaded onto a gel, if necessary amount of sample was adjusted to achieve 
same amount protein loading.  
   
Electrophoresis and blotting  
• Make SDS-Polyacrylamide gel using mini-gel module (165-3302, Bio-
Rad)  
• Load 10 µl of samples and one lane of protein size marker (161-0374, 
Bio-Rad) by Hamilton syringe or Geloader  tip (Eppendorf)  
• Separate proteins by elecrophoresis with constant current at 25 mA per 
mini-gel for 60 minutes or until the dye front reaches the end of the gel  
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• Stack a sandwich with 3 pieces of Whatman 3MM Chr paper, gel, 
0.45µm pore-size nitrocellulose membrane (10401196, Schleicher & 
Schuell), and another 3 pieces of Whatman 3MM Chr paper orderly 
• Transfer proteins to membrane with constant current (65-150 mA, 
depending on the size of the protein)  per mini-gel for 1 hour  
  
Blocking and antibody incubation  
• Rinse membrane with water  
• Incubate with Ponceau S solution (#33427, Serva) for 1 minute  
• Rinse with water several times and check total protein levels  
• Block with 5 % not-fat milk/ PBST for 1 hour  
• Incubate with primary antibody diluted in 5 % not-fat milk/ PBST at 4°C 
overnight  (some antibodies require 5% BSA instead of milk) 
• Rinse once and wash for 5 minutes 3 times with PBST  
• Incubate with HRP-conjugated secondary antibody (Jackson 
ImmunoResearch) diluted in 5 % milk/ PBST at room temperature for 1 
hour  
• Rinse once and wash for 10 minutes 3 times with PBST  
  
Chemiluminescent detection  
• Rinse once with PBS  
• Rinse with enhanced chemiluminescence reagent by mixing equal 
volumes of the Enhanced Luminol Reagent and the Oxidizing Reagent 
(NEL105, PerkinElmer)   
• Expose to Kodak X-OMAT AR Film for 30 seconds to 15 minutes  
  
Solutions   
Laemmli Sample Buffer 4X: 200mM Tris-base, 40% glycerol, 16% SDS, 20% 
β- mercaptoethanol, 0.01% bromphenolblue. 
PBST: 0.05 % Tween-20 in PBS 
 
Antibodies used: Anti-HA (Roche, 11867423001); anti-FLAG (Sigma, F1804) 
anti-pS6K(Thr398) (Cell Signaling 9209S); anti-tubulin (Developmental 
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Studies Hybridoma Bank, AA4.3); anti-4EBP1, anti-phosphoT37/46 4EBP1, 
anti-phosphoS656 4EBP1 (Cell Signaling); anti-GFP (Torrey Pines, New 
Jersey, USA). Secondary HRP-conjugated antibodies were from Jackson 
ImmunoResearch. 
 
7.6. Cap pull-down and Co-immunoprecipitation 
 
Cap pull-downs and co-immunoprecipitations were performed on mammalian 
or S2 cells, usually in a 6-well plate format. 
• Harvest cells by scraping, centrifuge at 3000 rpm to pellet the cells, 
remove all the supernatant (sup) 
• Lyse cells by fast pipetting up and down in 200 µl IP lysis buffer, 
incubate 5’ on ice, from now on all steps are on ice to avoid protein 
degradation 
• Spin down the nuclei at maximum speed in the 4°C, transfer the sup to 
a new tube 
• Remove 50 µl for input, add 17 µl 4X loading buffer (#R0891, 
Fermentas), boil for 5 min at  95°C, put on ice, freeze at -20°C 
• To 150 µl of sup add 350 µl of IP buffer and 30 µl of cap beads 
(m7GTP Sepharose 4B, Amersham), prewashed with 300 µl of IP 
buffer. 
• Incubate rocking for 1 hour at 4°C 
• Wash 3 times with 500 µl of IP buffer, spinning the beads down for 1 
min at 2000 rpm at 4°C 
•  Remove as much buffer as possible, add 60 µl of 2X sample buffer, 
boil for 5min at  95° C, put on ice, freeze at -20°C 
• run Western blot 
For immunoprecipitation, cells were lysed by pipetting up and down in ice-cold 
IP lysis Buffer with protease and phosphatase inhibitors. Lysates were cleared 
by centrifugation at 4°C at maximum speed for 15 min and incubated with 
antibody for 2 hr at 4°C. 50 µl of 50% agarose-protein A or G bead slurry was 
washed twice in lysis buffer and added to the antibody/cell-lysate mixture for 
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30 min. After three washes with cold lysis buffer, proteins were recovered with 
2X protein-gel loading buffer and heating for 5 min at 95°C. 
Solutions   
IP lysis Buffer: 50 mM Tris pH7.5, 150 mM NaCl, 1 % Triton X-100. 
Supplementary protease inhibitors: Protease Inhibitor Cocktail (Roche). 
Supplementary phosphatase inhibitors: 25 mM NaF, 1 mM Vanadate, and 25 
mM beta-Glycerolphosphate 
 
 
7.7. Cell culture 
 
Cell lines   
Cell lines used were obtained from ATCC (American Tissue Culture 
Collection). 
HeLa Kyoto (human)  
HEK-293 (human)  
COS-7 (monkey) 
S2 (Drosophila) 
 
Chemicals and solutions for cell culture were purchased from Gibco 
(Eggenstein, Germany). Transfection reagent, Fugene6, was purchased 
from Roche (Mannheim, Germany). 
Cell dishes with glass bottoms were purchased from MaTek (Ashland, USA)  
and welled cover slides (LabTek) from Nunc (Wiesbaden, Germany).  
Mammalian cell cultures were cultured at 37°C and 5% CO2. Mammalian 
cells were cultured in DMEM with 10% FCS  (Foetal Calf Serum, Sigma) and 
2mM L-glutamine and 100 µg/ml Pennicilin/Streptomycin antibiotics (Gibco). 
S2 cells were cultured in Drosophila SFM medium (Invitrogen) at 25°C and 
100 µg/ml Pennicilin/Streptomycin. S2 cells were transfected with Cellfectin 
(Invitrogen), according to the manufacturer instructions. 
 
Transient transfection of mammalian cells  
Cells were transfected at 40-60% confluency with 1 µg of total DNA using 
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Fugene6 in Optimem, according to the protocol of the manufacturer. Cells 
were incubated at 37°C and 5% CO2 to allow for protein expression. 
Expression time was usually between 15 and 48 h. If necessary cells were 
starved of serum overnight. 
 
7.8. Microscopy and FRET  
 
For imaging and detecting FRET two microscope setups were used. These 
were provided and maintained by EMBL Advanced Light Microscopy Facility 
(ALMF). 
Visitron System – widefield microscope Zeiss Axiovert from Carl Zeiss 
Mikroskopiesysteme (Jena, Germany) equipped with CCD camera 
Coolsnap HQ  from Photometrics, Roper Scientific, Inc. (Trenton, USA) and 
Filter wheel system from Visitron Systems GmbH (Puchheim, Germany)  
Leica AOBS SP2 - confocal microscope from Leica Microsystems 
(Heidelberg, Germany). 
 
7.8.1. Ratiometric FRET measurement 
Ratiometric imaging was done using an automated Axiovert 135 microscope 
(Zeiss) equipped with a 63x/1.4 NA oil immersion lens or a 40x/1.2 NA water 
immersion lens. Images were recorded with Cool Snap HQ cooled charge-
coupled device camera (Photometrics) using Metamorph software. Cell 
medium was replaced by Imaging medium (MEM, Sigma, M3024), with 30mM 
HEPES buffer, pH 7.2. The experiments were performed at 37°C in a heating 
chamber. The Insulin and Rapamycin were pre-dissolved in 100 µl medium 
before addition to the experiment. Samples were illuminated by a 100-watt 
mercury arc lamp through a D436/10 excitation filter and a CFP/YFP/Cy5 
triple-band beam splitter and imaged sequentially through 470/30 (ECFP) and 
535/30 (YFP) emission filters with the charge-coupled device camera set to 4 
x 4 binning.  If expression levels and fluorescence intensities were high 
enough, a 90% neutral grey filter was used to dim the excitation light. 
Exposure times were adjusted for each experiment, but were usually not 
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higher than 200 ms. Five different stage positions were usually recorded in 
one experiment. 
7.8.2. Image analysis 
If not otherwise mentioned, live cell FRET experiments were analyzed as 
follows: the fluorescence intensities of both channels (donor and acceptor) 
were directly taken from the unprocessed original microscope data set. 
Regions of interest (ROI) were defined, usually a whole cell and the 
background without cells. Mean fluorescence intensities were calculated using 
ImageJ (Rasband, 1997–2008). The background was subtracted for each 
time point and the ratio of acceptor/ donor mean intensities in the chosen ROI 
were calculated using Excel software. Cells chosen for analysis were visually 
healthy and usually expressed the probes to a medium level.  
7.8.3. Acceptor photobleaching 
Experiments were performed on a Leica AOBS SP2 equipped with strong 
lasers for photo-bleaching and making use of the FRET acceptor photo- 
bleaching module provided by the Leica software. First, reference pre-
bleaching pictures of the two fluorophores were taken. ECFP was excited with 
a 405 nm laser, FlAsH was excited using a 514 nm laser. Emission for ECFP 
was measured between 416 to 486 nm; for FlAsH between 520 to 600 nm. 
Subsequently, the acceptor was bleached using 514 nm laser at maximum 
power. Finally, images of both fluorophores were taken again after bleaching. 
Laser and PMT power were adjusted for each FRET experiment, but PMT 
values were set the same for both channels. To remove noise 4-line average 
was used.  
7.8.4. Sensitized emission 
Experiments were performed on a Leica AOBS SP2 making use of the FRET 
sensitized emission macro module provided by the Leica software. Initially 
sample containing only donor and acceptor fluorophores are used to calculate 
the correction factor for calculation of FRET efficiency. They describe the 
crosstalk between the channels. Three channels are recorded: channel A – 
donor channel (donor excitation/donor emission), channel B – FRET channel 
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(donor excitation/acceptor emission), channel C – acceptor channel (acceptor 
excitation/ acceptor emission).  Correction factors are defined as following: 
a = share of acceptor signal in the donor channel (channel A).  Correction 
factor from the acceptor sample = donor emission (donor excitation) / 
acceptor emission (acceptor excitation).   
b = share of donor signal in the FRET channel (channel B). Correction factor 
from the donor sample = acceptor emission (donor excitation) / donor 
emission (donor excitation). 
c = share of acceptor signal in the FRET channel (channel B). Correction 
factor from the acceptor sample = acceptor emission (donor excitation) / 
acceptor emission (acceptor excitation). 
After the correction factors are calculated it is crucial to leave the detection 
parameters (lasers power, PMTs and detectors windows) unchanged when 
FRET is measured.  There is a bug in the Leica confocal software, using 
sequential acquisition, the software does not change PMTs and detectors 
windows when switching from the first to the next acquisition step, and only 
laser is changed. Thus PMTs and detectors had the same settings for 
acquisition on all channels. ECFP was excited with a 405 nm laser, FlAsH 
was excited using a 514 nm laser. Emission for ECFP was measured 
between 430 to 510 nm; for FlAsH between 530 to 600 nm.  After background 
subtraction, FRET efficiency was calculated according to the following 
formula: 
FRETeff =( B - b*A - (c - a*b)*C)/C 
where A,B,C are detection channels and a.b,c are correction factors as 
explaned above. 
Finally to ensure that the Leica module was functioning properly I used raw 
data to analyze data manually using ImageJ and the same algorithm. The 
results were very similar to those produced by Leica software. 
 
7.8.5. FlAsH labeling and BAL experiments  
HeLa Kyoto cells were transiently transfected with DNA. The cells were 
labeled with FlAsH 24-48 h after transfection, according to the following 
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procedure (protocol from Cristiane Jost, Schultz lab, EMBL). FlAsH was a 
kind gift of Carsten Schultz lab (EMBL, Heidelberg).  
FlAsH was first incubated with 12.5 µM EDT, giving FlAsH-EDT2. FlAsH-EDT2 
was then used at a final concentration of 1 µM in a (microscope) dish and 
cells were incubated for 1 h at 37°C in Hank's Balanced Salt Solution (HBSS: 
10 mM HEPES, 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 2 mM CaCl2 and 1 
g/L Glucose at pH 7.3) supplemented with 1 g/L D-Glucose. After incubation, 
unbound and non-specifically bound FlAsH was removed by three 10 min 
washing steps with 200 µM EDT in Imaging medium. Finally, cells were left in 
the imaging medium at 37°C until imaging on the Leica AOBS SP2 confocal 
microscope. ECFP and FlAsH channels were monitored every 30sec for 6 
min. PMTs and detectors had the same settings for acquisition on both 
channels. ECFP was excited with a 405 nm laser, FlAsH was excited using a 
514 nm laser. Emission for ECFP was measured between 430 to 510 nm; for 
FlAsH between 530 to 630 nm. FlAsH labeling was destroyed by adding 5 mM 
British-Anti-Lewisite, (BAL, 2,3-dimercaptopropanol).  
 
7.9. Fly genetics 
7.9.1. Fly husbandry 
 
Flies were grown on standard corn meal molasses agar. All crosses were 
carried out at 25ºC unless indicated otherwise. Fly stock were stored at 18 ºC 
and flipped once a month.   
Fly food recipe: 
12 g agar, 18 g dry yeast, 10 g soy flour, 22 g turnip syrup, 80 g malt extract, 
80 g corn powder, 6.25 ml propionic acid, and 2.4 g methyl 4-
hydroxybenzoate (Nipagin) per liter. 
 
7.9.2. Fly strains  
All the fly strains used in this thesis are listed and annotated in Table 7.2 
including source or creator. Common stock means stocks propagated at 
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common EMBL fly room or from Cohen lab collections with not traceable 
origin. 
 
Table 7.2. Fly strains used for experiments  
 
Genotype Source Description 
tub-GAL4 Common stock tubulin-GAL4 
en-GAL4 Common stock engrailed-GAL4 
P(EP)2445 Bloomington CG7097 promoter insertion 
PBac(WH)CG7097(f04135) Bloomington CG7097 insertion 
P(lacW)l(2)SH1261 
Szeged stocks 
center CG7097 insertion 
W1118 Common stock white mutant, used as control 
OreR Bloomington wildtype 
Df(2R)Exel6069 Bloomington deficiency of CG7097 region 
l(2)SH1261excision lines 
1,2 Boris  Bryk excision lines 1,2 imprecise 
l(2)SH1261excision lines 
4,5 Boris  Bryk excision lines 4,5 precise 
daGAL4 Common stock daughterlessGAL4 
UAS-RhebAV4 Bloomington UAS-Rheb 
actGal4 Common stock actin-GAL4 
armGal4 Common stock armadillo-GAL4 
hsGal4 Common stock heatshock-GAL4 
eyeGal4 Common stock eyelessGal4 
apGal4 Common stock apterousGal4 
nubGal4 Common stock nubbinGal4 
ptcGal4 Common stock patchedGal4 
gig192 Bloomington TSC2 null 
Rhebdelta1 Bruce Edgar Rheb deletion 
Rhebdelta2 Bruce Edgar Rheb deletion 
chico1 Bloomington chico mutant 
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7.9.3. Ectopic expression using GAL4/UAS system 
 
GAL4/UAS system allows to express genes of interest in a temporally and 
spatially regulated manner in Drosophila (Brand and Perrimon, 1993). This 
system makes use of the yeast transcription activator, GAL4. GAL4 binds to 
its target sequence, UAS (upstream activation sequence), and thus activates 
transcription of attached gene. GAL4 can be expressed in many different 
patterns by placing it under the control of various Drosophila promoter 
sequences and activates expression of target gene or reporter placed 
downstream of UAS. In order to get ectopic expression of target gene 
according to the pattern of a specific promoter, transgenic line carrying GAL4 
driver under the specific promoter is crossed to another transgenic line 
carrying UAS followed by the coding sequence of target gene. 
 
7.10. Fat measurements 
Growth controlled males or wandering L3 larvae were used for triglycerides 
measurements in a two-step protocol. In the first step, homogenized 
triglycerides are hydrolysed by Lipoprotein Lipase (Sigma cat.62333) to fatty 
acids and glycerol and then glycerol amount is measured in a colorimetric 
reacton using Free Glycerol Reagent (Sigma cat. F6428). Amount of 
triglycerides was normalized to protein to account for differences in size and 
sample preparation. 
• Homogenize 5-8 flies in 200 µl of ice-cold Homogenization buffer using 
plastic tip, first smash the flies by hand and then 30 sec by electric 
homogenizer 
• add 300 µl of ice-cold Homogenization buffer  to have a final volume of  
500µl 
• incubate 5 min at 70ºC, cool to room temperature 
• take out 100µl  for Bradford (protein) measurement 
• spin debris 14000rpm for 3min, use 20µl of the supernatant to measure 
proteins (add 1ml of Bradford reagent (Bio-Rad), wait 5min, read 
absorbance at 595nm) 
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• to the remaining 400µl add 10µl of 10mg/ml Lipoprotein Lipase stock, 
mix 
• incubate overnight at 37ºC 
• spin debris 5000rpm for 1min 
• transfer 200µl to a new tube and spin at 14000rpm for 3 min 
• add 50µl sample (from the middle of liquid) to 800µl Free Glycerol 
Reagent (Sigma cat. F6428), incubate 6min at 37ºC 
• read absorbance at 540nm 
Solutions: 
Homogenization buffer - 0.05% Tween20 in H2O 
 
7.11. Size measurement  
7.11.1. Growth controlled condition  
  
In order to reduce the variation of growth caused by environmental factors 
(limited food and space), flies grew under controlled conditions. I collected 
embryos on apple juice agar plate from each cross for 12 hours. On the next 
day, I picked up first instar larvae and placed 50 larvae into a vial with fresh 
food. Flies grew up at 25°C until adulthood. Depending on the number of 
animals needed several collections were done. If not all progeny is of required 
genotype, scale up the collection according to Mendel’s Law.  
  
7.11.2.   Body weight  
  
Flies grew under controlled conditions as described in Section 7.10.1. Once 
the adult flies eclosed, I separated males and females into vials containing 
fresh food. I weighted two-day-old flies in a group of 50 males by 
microbalance.  
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7.11.3.    Growth rate/pupation 
  
First instar larvae were collected within 12 hours interval and placed in a 
batch of 50 into one vial of food as described in Section 7.10.1. The collection 
was done in triplicate. Pupae were counted every day from the day the 
pupation started.  
  
7.11.4.     Wing size  and cell size measurement 
  
Flies grew in a controlled condition as describe in Section 7.10.1. Matured 
adult flies were fixed in Glycerol/Ethanol for at least one day before 
dissection. Rinse fixed flies with distilled water several times and dissect out 
wings from main body in water. Mount wings in de Faure’s medium, leave a 
weight on top of coverslip, and allow it to dry overnight. Pictures were taken 
using 2.5X objective and digital camera (Leica DC 500) on Zeiss Axiophot 
Microscope. Wing areas were measured using ImageJ. At least 7 wings were 
measured to estimate experimental errors.  
For cell size, number of hairs in a fixed area between vein 5 and the posterior 
of the wing were counted in a 20X magnification image. Each cell in the wing 
epithelium produces a hair. To calculate cell size, the area was divided by the 
hair number. 
 
Reagents:  
Glycerol/ Ethanol  
20 % pure Glycerol in absolute Ethanol  
de Faure’s medium  
50 g Chloral hydrate (toxic), 30 g Gum Arabic, 20 ml Glycerol, and 50 ml 
distilled water  
 
7.12. Statistics 
 
All error bars in the graphs represent standard deviation. Significance was 
estimated by a two-tailed Student’s test, assuming unequal variance. 
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List of oigonucleotides used  for cloning and PCR 
 
Name 
Gene/Restriction 
site strand/position Primer sequence 5' to 3' 
OBB021 d4e-bp +Bgl II + agatctATGTCCGCTTCACCCACC 
OBB022 d4e-bp +Bgl II - agatctCAGATCCAGTTGGAACTGTTC 
OBB031 h4ebp1+BamH I + ggatccATGTCCGGGGGCAGCAGCTG 
OBB032 h4ebp1+Bgl II - agatctAATGTCCATCTCAAACTGTGACTCT 
OBB034 hum eIF4E - gaattcGTGGTGGAGCCGCTCTTAGT 
OBB035 hum eIF4E+EcoRI + gaattcGCGGTTGTGCGATCAGATC 
OBB036 hum eIF4E+NotI - gcggccgcGCTTGACGCAGTCTCCTATGA 
OBB037 hum eIF4E+NotI -1556 gcggccgcGGTTCAGCTCCCAAATCTC 
OBB038 
h eIF4E 28-
217+NcoI +937 ccatgGTTGCTAACCCAGAACACT 
OBB039 
h eIF4E 28-
217+KpnI -1487 ggtaccTTAAACAACAAACCTATTTTTAGTG 
OBB040 h eIF4E +NdeI +856 catATGGCGACTGTCGAACCG 
OBB041 h eIF4E +Xho I -1487 ctcgagTTAAACAACAAACCTATTTTTAGTG 
OBB042 4EBP1 +Nco I+2 + ccatggcgTCCGGGGGCAGCAGCTG 
OBB043 4EBP1 +Kpn I - ggtaccTTAAATGTCCATCTCAAACTGTGA 
OBB044 h eIF4E +NcoI +856 ccATGGCGACTGTCGAACCG 
OBB045 HAtag-NcoI up  catggcgtacccctacgacGTCCCGGACTATGCCGG 
OBB046 HAtag-NcoI bot  CATGCCGGCATAGTCCGGGACgtcgtaggggtacgc 
OBB047 Afl III h4ebp1 + acatgtATGTCCGGGGGCAGCAGCTG 
OBB048 BamH I h4ebp1 - GGATCCAATGTCCATCTCAAACTGTGACTCTTCAC 
OBB049 Afl III h4ebp1 new + acATGTCCGGGGGCAGCAGCTG 
OBB063 rp49 for qPCR + GCTAAGCTGTCGCACAAA 
OBB064 rp49 for qPCR - TCCGGTGGGCAGCATGTG 
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Name 
Gene/Restriction 
site strand/position Primer sequence 5' to 3' 
OBB077 EcoRI-4Cys-h4EBP1 + 
gaattcATGttcctgaactgctgccccggctgctgcatggagcccA
TGTCCGGGGGCAGCAGCTG 
OBB078 NotI 4EBP1 stop - gcggccgcTTAaatgtccatctcaaactgtg 
OBB079 EcoRI-h4EBP1 + gaattcATGTCCGGGGGCAGCAGCTG 
OBB080 
NotI -4Cys 4EBP1 
stop - 
gcggccgcTTAgggctccatgcagcagccggggcagcagttcag
gaaAATGTCCATCTCAAACTGTG 
OBB081 Age1 heIF4E + tcatctACCGGTggaATGGCGACTGTCGAACCG 
OBB082 XhoI heIF4E - tcatctctcgagTTAAACAACAAACCTATTTTTAGTG 
OBB083 KpnI heIF4E + ggtaccATGGCGACTGTCGAACCG 
OBB084 BamH I heIF4E - ggatccAACAACAAACCTATTTTTAGTG 
OBB085 EcoRI heIF4E + gaattcATGGCGACTGTCGAACCG 
OBB086 CG7097 + AACGTGGACAGCATTGTTTG 
OBB087 CG7097 - CTCTCCAAGGCCACAACC 
OBB088 CG5373 + CTGATGCCAGCCAAGCTC 
OBB089 CG5373 - CCTGGCGCAGATCATCAC 
OBB090 CG7097 - GCCTGTAGGTGCGACTCA 
OBB091 CG7097-RA +15 GCGTTGACGAAGTGCATGTG 
OBB092 CG7097-RA +505 GGCTGCCATCAAGGTCATCA 
OBB093 CG7097-RA +994 CAATCGAACTGGCTGAACTG 
OBB094 CG7097-RA +1492 CGACCTTGCCACTGAACAAC 
OBB095 CG7097-RA +1989 GATGCCGACGACGATGAACT 
OBB096 CG7097-RA +2445 GGCTTCTCGCATTCCAATAG 
OBB097 CG7097-RA +2998 CCGAGGAGGGCATCTACAAC 
OBB098 CG7097-RA +3493 CGATTGTGTGTACGGGTGTG 
 118 
Name 
Gene/Restriction 
site strand/position Primer sequence 5' to 3' 
OBB099 CG7097-RA +4022 CCCGCCCAATCCACTGTTAT 
OBB100 CG7097-RA +4496 AGTCAGCCAGCAGGAGAATC 
OBB101 HAtag-NheI up  ctagctacccctacgacgtcccggactatgcctaa 
OBB102 HAtag-NheI bot  ctagttaggcatagtccgggacgtcgtaggggtag 
OBB103 SH1261up 2224+ TCGGTTTCAATCCACCATGC 
OBB104 SH1261bot 2657- GGAGCAAACAAATTGGAGCAG 
OBB105 MAP4K3 7444- AAGATAGCGATTCGGGTCGAG 
OBB106 MAP4K3 7419- CCCGTCAGTGTGCATGGTAGT 
OBB107 MAP4K3 + GCTGCGACAACAACTTGAGAT 
OBB108 MAP4K3 - CGCAGGAGCCACAAATAAGTA 
OBB109 MAP4K3 + TGTGCTTGTGTGGGTTTGTTA 
OBB110 MAP4K3 - CCTTGCCCGTTACATTTACAT 
OBB111 MAP4K3 + CCTCGTTCTGCTCCACTGTGT 
OBB112 MAP4K3 - GCACAGCTCCTTCCTTCACTT 
OBB113 MAP4K3 + AGGAAGGGAAAGGCAAAAACT 
OBB114 MAP4K3 - GCGTGGTGAGCAATAATGATA 
OBB115 MAP4K3 + TTTGAGAACCATCGGTATTGA 
OBB116 MAP4K3 - CCACCGAAAATGTTATAAGGA 
OBB117 MAP4K3 + GCAAACAAAAGGCAAAGAAAT 
OBB118 MAP4K3 - CAATCCAATGAGGCAATAGTG 
OBB119 CG11968+NotI + gcggccgcAAGAAAAAGGTGTTACTGATGGG 
OBB120 CG11968+XhoI - ctcgagCGGCAAATGGAGTTATGGAA 
OBB121 CG8707+NotI + gcggccgcAGCTACGATGATGATGACTATCC 
OBB122 CG8707+XhoI - ctcgagTTTTTTACGCTGCTCTGTGA 
OBB123 FLAGtag-NotI up + ggccATGGACTACAAGGACGACGACGACAAG 
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Name 
Gene/Restriction 
site strand/position Primer sequence 5' to 3' 
OBB124 FLAGtag-NotI bot - ggccCTTGTCGTCGTCGTCCTTGTAGTCCAT 
 
Note: Lower case usually denotes restriction site sequence followed by a 
gene specific sequence in upper case.  
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